Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 2208. Отображено 100.
25-04-2013 дата публикации

TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING HEPARIN

Номер: US20130102564A1
Автор: Virno Michele
Принадлежит: ADVANCE HOLDINGS LIMITED

The present invention relates to a topical pharmaceutical composition comprising heparin and to the use thereof for preventing a functional complication of A-V fistulas and A-V grafts in chronic haemodialysis patients. 1. Topical pharmaceutical formulation comprising a solution of heparin and at least one polyoxyalkylene ester of a hydroxy fatty acid.2. Pharmaceutical formulation for the topical application of heparin , wherein said formulation is a solution of heparin and at least one polyoxyalkylene ester of a hydroxy fatty acid.3. Pharmaceutical formulation according to or , wherein said formulation is an aqueous solution.4. Pharmaceutical formulation according to claim 3 , wherein said aqueous solution further comprises at least one alcohol.5. Pharmaceutical formulation according to claim 4 , wherein said alcohol is selected from the group comprising pharmaceutically acceptable alcohols claim 4 , preferably ethanol claim 4 , 1-propanol claim 4 , 2-propanol claim 4 , and mixture thereof.6. Pharmaceutical formulation according to any one of preceding claims claim 4 , wherein said at least one polyoxyalkylene ester of a hydroxy fatty acid is selected from the group consisting of esters of a hydroxy fatty acid having from 8 to 30 carbon atoms claim 4 , preferably from 14 to 24 carbon atoms claim 4 , with a polyoxyalkylene having a molecular weight ranging from 200 to 6 claim 4 ,000 claim 4 , preferably from 400 to 1 claim 4 ,500.7. Pharmaceutical formulation according to claim 6 , wherein said at least one polyoxyalkylene ester of a hydroxy fatty acid is a polyglycol ester of polyethylene glycol and 12-hydroxystearic acid (Macrogol 15 hydroxystearate).8. Pharmaceutical formulation according to any one of preceding claims claim 6 , for the treatment or prevention of a functional complication of A-V fistulas and A-V grafts in chronic haemodialysis patients.9. Pharmaceutical formulation according to claim 8 , wherein said functional complication is the neointimal ...

Подробнее
Номер записи: 1
02-05-2013 дата публикации

Topical Itraconazole Formulations and Uses Thereof

Номер: US20130109700A1
Автор: Beachy Philip A., Epstein, JR. Ervin H., Kim James, Rajadas Jayakumar, Tang Jean
Принадлежит:

Methods of transdermally delivering a therapeutic amount of a triazole-triazolone compound are provided, e.g. for the prevention or treatment of basal cell carcinoma (BCC) in a subject. A therapeutic level of a triazole-triazolone compound such as itraconazole is delivered transdermally to a subject. Also provided are topical triazole-triazolone compositions that find use in practicing the subject methods. 1. A method for treating or preventing basal cell carcinoma (BCC) in a subject , the method comprising:contacting a topical surface of the subject with a transdermal triazole-triazolone composition comprising the triazole-triazolone compound; anddelivering a therapeutic amount of a triazole-triazolone compound.2. The method according to claim 1 , wherein said transdermal composition is a patch claim 1 , a gel claim 1 , a cream claim 1 , a foam claim 1 , a lotion claim 1 , a spray claim 1 , an ointment.3. The method of claim 2 , wherein said triazole-triazolone compound is present in the composition in an amount of from about 0.5 weight % to about 50 weight %.4. The method of claim 1 , wherein said triazole-triazolone compound is itraconazole.5. The method of claim 3 , wherein the composition further comprises a cyclodextrin.6. The method of claim 3 , wherein the composition further comprises one or more hydrophobic oils.7. The method of claim 3 , wherein the composition further comprises an emulsifier.8. The method of claim 3 , wherein the composition further comprises an emollient.9. The method of claim 3 , wherein the composition further comprises a surfactant.10. The method of claim 1 , wherein the method provides a therapeutic level of a triazole-triazolone compound in the dermis of the subject where a tumor is located.11. A pharmaceutical formulation for transdermal delivery of itraconazole.12. The formulation of claim 11 , wherein the formulation comprises a cyclodextrin.13. The formulation of claim 12 , wherein the composition further comprises one or more ...

Подробнее
Номер записи: 2
16-05-2013 дата публикации

Stable Topical Composition and a Process for Producing a Stable Topical Composition

Номер: US20130123220A1
Автор: Queiroz Dinalva Brito de
Принадлежит: EVIDENCE SOLUÇÕES FARMACÊUTICAS LTDA EPP

The present invention is directed to a suitable topical composition for cosmetic, pharmaceutical or dermatological use. In a particular aspect, it is a stable nanoemulsion whose particles have a narrow size distribution range. In another particular aspect, the invention is directed to an improved process for producing said composition. 1. A stable topical composition , characterized by the fact that it consists of at least (a) one nanoemulsion that comprises at least one non-ionic emulsifying agent , at least one amphoteric surfactant , at least one emollient , at least one humectant , and at least one hydrating agent , and (b) one or more active principles incorporated to the oleous globules of said nanoemulsion , optionally in the presence of one or more amongst oxygen-carrying agents , oleous vehicles , permeation promoters and hydrating agents.2. The topical composition according to claim 1 , characterized in that said emulsifying agent is one or more amongst cetearyl claim 1 , sorbitan and ceteareth from mixtures of salts of fatty acids resulting from the saponification of vegetable oil claim 1 , for example claim 1 , coconut oil (cocoate) claim 1 , palm oil (palmate) claim 1 , olive oil (olivate) claim 1 , soy oil (soyate) claim 1 , sunflower seed oil claim 1 , or animal oil (tallowate).3. The topical composition according to claim 1 , characterized in that said emulsifying agent is one or more amongst cetearyl claim 1 , sorbitan and ceteareth from mixtures of salts of fatty acid resulting from the saponification of olive oil (olivate).4. The topical composition according to claim 1 , characterized in that said amphoteric surfactant is one or more amongst saponines claim 1 , lecithin and soy protein.5. The topical composition according to claim 1 , characterized in that said amphoteric surfactant is lecithin.6. The topical composition according to claim 1 , characterized in that said emollient comprises one or more fatty acids chosen among those (a) having a ...

Подробнее
Номер записи: 3
16-05-2013 дата публикации

TRANSDERMALLY DELIVERABLE OPIOID PRODRUGS, ABUSE-RESISTANT COMPOSITIONS AND METHODS OF USING OPIOID PRODRUGS

Номер: US20130123292A1
Автор: GOLINSKI Miroslaw Jerzy, HAMMELL Dana Carmel, HOWARD Jeffery Lynn, STINCHCOMB Audra Lynn
Принадлежит: AllTranz Inc.

Described herein are opioid prodrugs, methods of making opioid prodrugs, formulations comprising opioid prodrugs, and methods of using opioid prodrugs. One embodiment described herein relates to the transdermal administration of a buprenorphine prodrug in an abuse-resistant formulation for treating and preventing diseases and/or disorders. 3. The method of wherein the medical condition is selected from the group consisting of: opioid dependence claim 2 , alcohol dependence and pain.5. The method of wherein the medical condition is selected from the group consisting of: opioid dependence; alcohol dependence and pain.6. The method of further comprising the step of transdermally administering a second compound selected from the group consisting of: naltrexone; 3-O-pivalyl naltrexone; 3-O-isovaleryl naltrexone; 3-O-(2′-ethylbutyryl)naltrexone; 3-O-isobutyryl naltrexone; 3-O-isopropyloxycarbonyl naltrexone; 3-O-tertiarybutyloxycarbonyl naltrexone; N claim 2 ,N-dimethyl-3-O-carbamate naltrexone; N claim 2 ,N-diethyl-3-O-carbamate naltrexone; and N claim 2 ,N-diisopropyl-3-O-carbamate naltrexone. This application is a continuation of U.S. application Ser. No. 12/388,122, filed on Feb. 19, 2009, which is a continuation of U.S. application Ser. No. 11/860,432, filed on Sep. 24, 2007, now U.S. Pat. No. 7,511,054, which claims the benefit of U.S. Provisional Application Ser. No. 60/826,603 filed Sep. 22, 2006. These applications, in their entirety, are hereby incorporated by reference.Described herein are pharmaceutically active agents suitable for transdermal delivery to a mammal, compositions for transdermal delivery of pharmaceutically active agents and methods of using such compositions in treating and preventing diseases and disorders.Pain is the most frequently reported symptom and is a common clinical problem which confronts the clinician. Millions of people in the United States suffer from severe pain that, according to numerous recent reports, is chronically under- ...

Подробнее
Номер записи: 4
06-06-2013 дата публикации

DEPOSITION OF SUPERALLOYS USING POWDERED FLUX AND METAL

Номер: US20130140278A1
Автор: Bruck Gerald J., Kamel Ahmed
Принадлежит:

A method for depositing superalloy materials. A layer of powder () disposed over a superalloy substrate () is heated with an energy beam () to form a layer of superalloy cladding () and a layer of slag (). The layer of powder includes flux material and alloy material, formed either as separate powders or as a hybrid particle powder. A layer of powdered flux material () may be placed over a layer of powdered metal (), or the flux and metal powders may be mixed together (). An extrudable filler material () such as nickel, nickel-chromium or nickel-chromium-cobalt wire or strip may be added to the melt pool to combine with the melted powder to give the superalloy cladding the composition of a desired superalloy material. 1. A method comprising:cleaning a surface of a superalloy substrate, the superalloy substrate comprising a composition beyond a zone of weldability defined on a graph of superalloys plotting titanium content verses aluminum content, wherein the zone of weldability is upper bounded by a line intersecting the titanium content axis at 6 wt. % and intersecting the aluminum content axis at 3 wt. %;pre-placing or feeding a layer of powdered material comprising flux material and metal material onto the cleaned surface;melting the powdered material into a melt pool and floating slag layer, the melt pool having a composition of a desired superalloy material comprising a composition beyond the zone of weldability;allowing the melt pool and slag layer to cool and solidify, leaving a layer of the desired superalloy material clad over the superalloy substrate; andpost weld heat treating the clad superalloy material and substrate superalloy material without weld solidification cracking and strain age cracking.2. The method of claim 1 , further comprising:pre-placing the layer of powdered material as mixed flux and superalloy powder to a depth from 2.5 to 5.5 mm; andmelting the powdered material with laser energy at a power level from 0.6 to 2 kilowatts using ...

Подробнее
Номер записи: 5
06-06-2013 дата публикации

METHOD FOR INSTALLING A DOUBLE BEARING IN A CASTING, WHEEL COMPRISING A DOUBLE BEARING, AND JOINT WITH DOUBLE BEARING

Номер: US20130142469A1
Автор: LINDFORS Erik
Принадлежит: KONE CORPORATION

A method for installing a casting double bearing in a casting, and a wheel manufactured according to the method are provided. The double bearing includes at least two bearing units that are essentially similar. The method includes at least the following phases: a double bearing is formed by disposing two bearings next to each other side-by-side and by placing a separator that forms a gap between the bearings such that the separator rests on at least one of outer surface of the outer rim of a bearing, and the separator part of the separator is disposed between the side surfaces that face each other of the outer rims of the bearings; the formed double bearing is placed in the casting mold in the correct position; and the casting is cast around the double bearing 1. A method for installing a double bearing in a casting , which double bearing comprises at least two bearing units that are essentially similar to each other , wherein the method comprises the steps of:forming a double bearing by disposing two bearings next to each other side-by-side and by placing a separator that forms a gap between the bearings such that the separator rests on the outer surface of the outer rim of at least one bearing and the separator part of the separator is disposed between the side surfaces that face each other of the outer rims of the bearings;placing the formed double bearing in the casting mold in the correct position; andcasting around the double bearing.2. The method according to claim 1 , wherein before casting claim 1 , the separator is supported on the outer surface of the outer rim of both bearings and the separator part of the separator is disposed between the side surfaces that face each other of the outer rims of the bearings.3. The method according to claim 1 , wherein the casting is cast around the double bearing as a diecast.4. The method according to claim 1 , wherein the separator is arranged to melt or to soften at least partly and the separator is allowed to harden ...

Подробнее
Номер записи: 6
20-06-2013 дата публикации

SYSTEM AND METHOD FOR UTILIZATION OF SHROUDED PLASMA SPRAY OR SHROUDED LIQUID SUSPENSION INJECTION IN SUSPENSION PLASMA SPRAY PROCESSES

Номер: US20130157040A1
Автор: Feuerstein Albert, III Thomas F., Lemen Don J., Lewis, McCoy Mark, Petorak Christopher A.
Принадлежит:

A system and method for producing thermal spray coatings on a substrate from a liquid suspension is disclosed. The disclosed system and method include a thermal spray torch for generating a plasma and a liquid suspension delivery subsystem for delivering a flow of liquid suspension with sub-micron particles to the plasma to produce a plasma effluent. The liquid suspension delivery subsystem comprises an injector or nozzle which can produce an inert or reactive gas sheath partially or fully surrounding the plasma effluent. A sheath can also be used to isolate injection of the liquid suspension. A gas assist stream can also be employed at or near the suspension injection point. The shroud, sheath or gas assist technique can retain the sub-micron particles entrained within the plasma effluent and substantially prevent entrainment of ambient gases into the plasma effluent. The liquid suspension delivery subsystem can be arranged as an axial injection system, a radial internal injection system or an external radial injection system. 1. A thermal spray system for producing coatings on a substrate from a liquid suspension comprising:a thermal spray torch for generating a plasma;a liquid suspension delivery subsystem for delivering a flow of the liquid suspension with sub-micron particles; anda nozzle assembly for delivering the plasma from the thermal spray torch to the liquid suspension to produce a plasma effluent, the nozzle assembly adapted for producing an inert gas shroud substantially surrounding said plasma effluent;wherein the inert shroud is configured to substantially retain entrainment of the sub-micron particles in the plasma effluent and substantially inhibit gases from entering and reacting with the plasma effluent.2. The thermal spray system of claim 1 , wherein the shroud extends from the nozzle assembly to the substrate surface.3. The thermal spray system of claim 1 , wherein the shroud is a laminar flowing shield.4. The thermal spray system of claim 1 , ...

Подробнее
Номер записи: 7
27-06-2013 дата публикации

TOPICAL TREATMENT WITH DAPSONE IN G6PD-DEFICIENT PATIENTS

Номер: US20130165526A1
Автор: Garret John S.
Принадлежит: ALLERGAN, INC.

The present invention provides a pharmaceutical carrier system comprising a dermatological composition that is a semi-solid aqueous gel, wherein dapsone is dissolved in the gel such that the dapsone has the capacity to cross the stratum corneum layer of the epidermis, and wherein the composition also contains dapsone in a microparticulate state that does not readily cross the stratum corneum of the epidermis. The present invention also provides methods of treating dermatological conditions in G6PD-deficient patients with the composition, while avoiding adverse hematologic effects. 1. A method to treat a dermatological condition in a glucose-6-phosphate dehydrogenase-deficient patient comprising applying a dermatological composition to said condition , wherein said dermatological composition comprises dapsone.2. The method of claim 1 , wherein the dermatological composition comprises dissolved dapsone and microparticulate dapsone.3. The method of claim 1 , wherein the dermatological condition is selected from the group consisting of inflammatory acne claim 1 , non-inflammatory acne and rosacea.4. A method to treat a dermatological condition in a glucose-6-phosphate dehydrogenase-deficient patient comprising applying topically a dermatological gel composition including microparticulate pharmaceutical and dissolved pharmaceutical claim 1 , which comprises:a thickening agent;water;a high-boiling, nonionic organic solvent;a preservative;dapsone in a microparticulate and dissolved state;and a base solution.5. The method of claim 4 , wherein the ratio of microparticulate to dissolved dapsone is no greater than 5.6. The method of claim 4 , wherein the dermatological condition is selected from the group consisting of inflammatory acne claim 4 , non-inflammatory acne and rosacea.8. The method of claim 7 , wherein the dermatological condition is selected from the group consisting of inflammatory acne claim 7 , non-inflammatory acne and rosacea.9. A method to treat acne in a ...

Подробнее
Номер записи: 8
01-08-2013 дата публикации

Transdermal Hormone Delivery

Номер: US20130195956A1
Автор: ARNOLD Charles G., BANGA Ajay K., KYDONIEUS Agis, ROSSI Thomas M., SACHDEVA Vishal
Принадлежит: Agile Therapeutics, Inc.

Compositions and devices for transdermal hormone delivery are disclosed. The compositions and devices include desogestrel and enable delivery of effective amounts of progestin without the use of skin permeation enhancers. 1. A composition for transdermal delivery of a progestin for effecting contraception in a woman , said composition being a polymeric PSA matrix comprising a PSA and an effective amount of desogestrel , wherein the composition does not comprise a skin penetration enhancer.2. The composition of wherein the carrier comprises PVP claim 1 , PVP/VA claim 1 , or mineral oil or a combination of PVP or PVP/VA and mineral oil.3. The composition of wherein the PSA is a PIB or an acrylate.4. The composition of wherein the PSA is a PIB.5. The composition of wherein thePIB PSA is mixture of about 10% high molecular weight PIB claim 4 , about 50% low molecular weight PIB claim 4 , and about 40% polybutene.6. The composition of wherein the PSA is a polyacrylate adhesive copolymer having a 2-ethylhexyl acrylate monomer and approximately 50-60% w/w of vinyl acetate as a co-monomer.7. The composition of wherein the progestin is present in an amount of 1 to 10 wt % based on the weight of the polymeric matrix.8. The composition of that comprises (a) 70 to 95 wt % PIB claim 1 , (b)(i) 1 to 20 wt % mineral oil or 0.1 to 10 wt % PVP or PVP/VA or (ii) 1 to 20 wt % mineral oil and 0.1 to 10 wt % PVP or PVP/VA claim 1 , and (c) 1 to 10 wt % desogestrel.9. The composition of that comprises 80 to 90 wt % PIB claim 8 , 5 to 15 wt % mineral oil claim 8 , 0.1 to 5 wt % PVP/VA claim 8 , and 2 to 6 wt % desogestrel (total polymeric PSA matrix=100 wt %) and having a surface area of about 15 cm.10. The composition of that has a surface area of 5 to 20 cmand a thickness of 0.1 to 0.6 mm.11. The composition of that has a surface area of about 15 cmand a thickness of 0.2 to 0.4 mm.12. The composition of that also comprises an estrogen.13. The composition of wherein the estrogen is ...

Подробнее
Номер записи: 9
01-08-2013 дата публикации

Method of Providing Sustained Analgesia With Buprenorphine

Номер: US20130197020A1
Автор: Goldenheim Paul D., KAIKO Robert F., Reder Robert F.
Принадлежит: Purdue Pharma L.P.

A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval. 167-. (canceled)68. A method of treating pain in a human patient , comprisingadministering buprenorphine base transdermally to said human patient by applying a transdermal delivery system to the skin of a patient, and maintaining said transdermal delivery system in contact with the patient's skin for a seven day dosing interval, said transdermal delivery system maintaining a mean relative release rate of from about 3 ug/hr to about 86 ug/hr and providing a substantially first order plasma level increase of buprenorphine from the initiation of the dosing interval until about 72 hours after the initiation of the dosing interval; and a mean relative release rate of about 0.3 ug/hr to about 9 ug/hr and providing a substantially zero order plasma level fluctuation of buprenorphine from about 72 hours after the initiation of the dosing interval until the end of the seven-day dosing interval, such that the following mean plasma concentrations are achieved:a mean plasma concentration from about 0.3 to about 113 pg/ml at about 6 hours after initiation of the dosing interval;a mean plasma concentration from about 3 to about 296 pg/ml at about 12 hours after initiation of the dosing interval;a mean plasma concentration from about 7 to about 644 pg/ml at about 24 hours after initiation of the dosing interval;a mean plasma concentration from about 13 to about 753 pg/ml at about 36 hours after initiation of the dosing interval;a mean plasma ...

Подробнее
Номер записи: 10
01-08-2013 дата публикации

TRANSDERMAL ABSORPTION PREPARATION

Номер: US20130197036A1
Автор: Jo Rumi, Kouno Ryoji, Kubo Yoshiko, Yoshimura Misaki
Принадлежит: Toyama Chemical Co., Ltd.

Disclosed is a safe, transdermal absorption preparation useful in the treatment of fungal infections, having excellent skin permeability and strong antifungal activity, and greatly contributing to a patient's quality of life. The disclosed transdermal absorption preparation contains 4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-1-piperidinyl]propoxy}benzamidine, or a salt thereof, and a transdermal absorption enhancer. 1. A transdermal preparation , comprising:4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-1-piperidinyl]propoxy}benzamidine or a salt thereof; anda transdermal absorption enhancer.2. The transdermal preparation of claim 1 , wherein the transdermal absorption enhancer is a higher alcohol claim 1 , a higher monocarboxylic acid claim 1 , a higher monocarboxylic acid ester claim 1 , an aromatic monoterpene claim 1 , a non-aromatic monoterpene having no polar group claim 1 , or any mixture thereof.3. The transdermal preparation of claim 2 , wherein the higher alcohol is a saturated alcohol comprising 8 to 18 carbon atoms or a non-saturated alcohol comprising 8 to 18 carbon atoms; the higher monocarboxylic acid is a saturated fatty acid comprising 8 to 18 carbon atoms or a non-saturated fatty acid comprising 8 to 18 carbon atoms; the higher monocarboxylic acid ester is a reaction product of a monocarboxylic acid comprising 6 to 18 carbon atoms and an alcohol comprising 1 to 6 carbon atoms.4. The transdermal preparation of claim 2 , wherein the higher alcohol is octanol claim 2 , decanol claim 2 , lauryl alcohol claim 2 , myristyl alcohol or oleyl alcohol; the higher monocarboxylic acid is caprylic acid claim 2 , capric acid claim 2 , lauric acid claim 2 , myristic acid claim 2 , oleic acid claim 2 , linoleic acid or linolenic acid; the higher monocarboxylic acid ester is ethyl caproate claim 2 , ethyl laurate claim 2 , isopropyl myristate or isopropyl palmitate; the aromatic monoterpene is cymene or thymol; and the non-aromatic monoterpene having no ...

Подробнее
Номер записи: 11
08-08-2013 дата публикации

SYSTEMS AND METHODS FOR THE FABRICATION OF TISSUE PATCHES

Номер: US20130202675A1
Автор: Ericson Daniel Grant
Принадлежит: Dynasil Biomedical Corporation

Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment. 1. A method of preparing a tissue adherent patch , comprising:applying a compressive force to a liquid containing composition comprising fibrin and/or fibrinogen;passing at least a portion of a liquid component of the composition through a filter so that at least a portion of the fibrin and/or fibrinogen is separated from the at least a portion of the liquid component; andpolymerizing the fibrinogen to form fibrin and/or cross-linking the fibrin to form a solid matrix comprising cross-linked fibrin, whereinthe tissue adherent patch comprises or is formed from the solid matrix.2. A method of preparing a tissue adherent patch , comprising:applying a compressive force to a liquid containing composition comprising fibrin and/or fibrinogen within a chamber; andpolymerizing the fibrinogen to form fibrin and/or cross-linking the fibrin to form a solid matrix comprising cross-linked fibrin, whereinthe tissue adherent patch comprises or is formed from the solid matrix.3. The method of claim 1 , wherein the liquid-containing composition comprises whole blood.4. The method of claim 1 , wherein the liquid-containing composition comprises a plasma component of whole blood.5. The method of claim 1 , wherein the liquid-containing composition comprises a curing agent.6. The method of claim 5 , wherein the curing agent comprises thrombin.7. The method of claim 5 , wherein the curing agent comprises a calcium-containing compound.8. The method of claim 1 , wherein the liquid-containing composition comprises at least a part of a blood sample removed from a subject.9. The method of claim 8 , comprising applying the patch to the subject from which the blood sample is removed.10. The method of claim 1 , wherein the compressive force is ...

Подробнее
Номер записи: 12
15-08-2013 дата публикации

ARIPIPRAZOLE COMPOSITIONS AND METHODS FOR ITS TRANSDERMAL DELIVERY

Номер: US20130209552A1
Автор: HOSSAIN Muhammed Anwar, Plakogiannis Fotios M.
Принадлежит: TRANSDERMAL RESEARCH PHARM LABORATORIES, LLC

The present invention discloses compositions of liquid and gel formulation containing aripiprazole in the form of a patch for transdermal delivery. 1. A pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery.2. The pharmaceutical composition of wherein the aripirazole is in a gel or liquid form.3. The pharmaceutical composition of wherein the aripirazole is present in the amount of 1 to 20% w/v.4. The pharmaceutical composition of wherein the aripirazole is present in the amount of 1 to 20% w/v.5. The pharmaceutical composition of wherein the gel contains a gelling agent in the range of about 0.1% to 5% w/v.6. The pharmaceutical composition of further comprising approximately 40% N-methyl-2-pyrrolidone claim 1 , 40% DiMethylsulfoxide claim 1 , 15% alcohol and 5% water.7. The pharmaceutical composition of being in the form of a liquid and comprising an alcohol claim 1 , glycol claim 1 , mineral oil claim 1 , and/or vegetable oil.8. The pharmaceutical composition of wherein the composition is in a gel form and further comprises a gelling agent selected from the group consisting of natural polymers claim 2 , semisynthetic polymers claim 2 , synthetic polymers claim 2 , carboxyvinyl polymers or carbomers claim 2 , carbopol 940 claim 2 , carbopol 934 claim 2 , carbopol 971 claim 2 , poloxamer claim 2 , polyacrylamide claim 2 , polyvinyl alcohol claim 2 , polyethylene and co-polymers thereof.9. The pharmaceutical composition of wherein the form is a patch for transdermal delivery.10. The pharmaceutical composition of being in the dosage form of an ointment claim 1 , cream claim 1 , emulsion claim 1 , or liposome.11. The pharmaceutical composition of wherein the aripirazole is present in the amount of 1 to 20% w/v.12. The pharmaceutical composition of further comprising an enhancer.13. The pharmaceutical composition of wherein the enhancer is selected from the group consisting of lauric acid claim 12 , myristc acid claim 12 , water ...

Подробнее
Номер записи: 13
15-08-2013 дата публикации

STABLE TOPICAL COMPOSITIONS FOR 1,2,4-THIADIAZOLE DERIVATIVES

Номер: US20130210868A1
Автор: CUI Chengji, NG Shirley Mei-king, WONG George, YUSUF Mohammed, ZHANG Fa
Принадлежит: JANSSEN PHARMACEUTICAL, INC.

The present application provides a stable topical composition comprising a compound of 1,2,4-thiadiazole derivatives and the related thiourea derivatives. The stable topical composition may be present in various forms, including aqueous gel, cream, and emulsion. The stable topical composition may be stored at refrigerated or ambient condition for a reasonable shelf-life. The present application also provides a method of treating dermatologic disorders mediated by a melanocortin receptor using the stable topical composition. The stable composition may be delivered using a single chamber or dual chamber device. A method of preparing and delivering the stable composition is also provided. 2. The method of claim 1 , wherein said aqueous gel and said base are mixed in a weight ratio of 1:9 to 9:1.3. The method of claim 1 , wherein said aqueous gel and said base are mixed in a weight ratio of 1:4 to 4:1.4. The method of claim 1 , wherein said aqueous gel and said base are mixed in a weight ratio of 1:2 to 2:1.5. The method of claim 1 , wherein said aqueous gel and said base are mixed in a weight ratio of 1:1.6. The method of claim 1 , wherein said compound is selected from the group consisting of 2-(2-methoxyphenyl)-3-(2-methoxyphenyl)-5-phenylamino-[1 claim 1 ,2 claim 1 ,4]-thiadiazol-2-ium claim 1 , [2-(2-methoxyphenyl)-3-(2-methoxyphenyl)-2H-[1 claim 1 ,2 claim 1 ,4]-thiadiazol-5-ylidene]-phenylamine claim 1 , 1-[(2-methoxy-phenyl)-(2-methoxy-phenylamino)-methylene]-3-phenyl-thiourea claim 1 , 1-[(2-methoxy-phenyl)-(2-methoxy-phenylimino)-methyl]-3-phenyl-thiourea; and pharmaceutically acceptable salts thereof.7. The method of claim 1 , wherein said viscosity modifying agent is selected from the group consisting of acacia claim 1 , agar claim 1 , alginic acid claim 1 , bentonite claim 1 , carbomer copolymer claim 1 , carbomer homopolymer claim 1 , and carbomer interpolymer claim 1 , carboxymethylcellulose calcium claim 1 , carboxymethylcellulose sodium claim 1 , ...

Подробнее
Номер записи: 14
22-08-2013 дата публикации

PHARMACEUTICAL COMPOSITIONS AND DELIVERY DEVICES COMPRISING STINGING CELLS OR CAPSULES

Номер: US20130216603A1
Автор: Ayalon Ari, Eckhouse Shimon, Lotan Tamar
Принадлежит: NANOCYTE (ISRAEL) LTD.

A pharmaceutical composition is provided. The pharmaceutical composition comprises as an active ingredient a tropane alkaloid drug or a muscarinic receptor antagonist and stinging cells or capsules. 1. A pharmaceutical composition comprising as an active ingredient scopolamine and stinging cells or capsules and a pharmaceutically acceptable carrier.2. (canceled)3. The pharmaceutical composition of claim 1 , wherein said active ingredient is disposed in a liquid surrounding claim 1 , or stored within claim 1 , said stinging cells or capsules.4. A delivery device comprising a support which serves for supporting the stinging cells or capsules of the pharmaceutical composition of and for applying it to an outer surface of a tissue region into which delivery is desired.510-. (canceled)11. The pharmaceutical composition of wherein said pharmaceutically acceptable carrier is selected from the group consisting of an aqueous solution claim 1 , a gel claim 1 , an oil and semi solid formulation.12. The pharmaceutical composition of claim 3 , wherein said stinging capsules are capable of delivering upon discharge said liquid disposed in or around said stinging capsules into a tissue.13. The device of claim 4 , further comprising a mechanism for triggering discharge of said stinging capsules or cells.14. The device of claim 13 , wherein said mechanism is selected from the group consisting of a chemical triggering mechanism and an electrical triggering mechanism.15. The device of claim 4 , wherein said support is selected from the group consisting of a patch claim 4 , a foil and a plaster.16. The device of claim 4 , wherein said tissue region is a skin.17. The pharmaceutical composition of claim 1 , wherein said stinging cells or capsules are from Nematostella vectensis. This application claims priority from U.S. Provisional Patent Application No. 61/407,073 filed on Oct. 27, 2010, the contents of which is hereby incorporated by reference in its entirety.The present invention, in ...

Подробнее
Номер записи: 15
12-09-2013 дата публикации

ADDITION OF LITHIUM ALUMINATE TO IMPROVE THE PERFORMANCE OF SELF SHIELDED ELECTRODES

Номер: US20130233840A1
Автор: KEEGAN James M.
Принадлежит: LINCOLN GLOBAL, INC.

A self-shielding welding electrode and a method of making the same are provided. The self-shielding welding electrode contains lithium aluminate in either the flux or the electrode portion of the electrode. 124-. (canceled)25. A welding electrode , comprising:a metallic electrode portion, anda flux portion adjacent to the metallic electrode portion,wherein at least one of said metallic electrode portion and flux portion contains at least one of lithium aluminate and lithium zirconate, andwherein the flux portion contains both lithium aluminate and magnesium oxide, and wherein the flux portion contains about 1 to about 15% by weight of lithium aluminate and magnesium oxide combined.26. A welding electrode , comprising;a metallic electrode portion, anda flux portion adjacent to the metallic electrode portion,wherein at least one of said .metallic electrode portion and flux portion contains lithium aluminate, and at least one of magnesium oxide and cerium oxide.27. The welding electrode of claim 26 , wherein the electrode does not contain lithium ferrate.28. The welding electrode of claim 26 , wherein the flux portion contains up to about 8% by weight of magnesium oxide.29. The welding electrode of claim 26 , wherein the flux claim 26 , portion contains about 1 to about 15% by weight of magnesium oxide claim 26 ,30. The welding electrode of claim 26 , wherein the flux portion contains up to about 12% by weight claim 26 , of cerium oxide.31. A welding electrode claim 26 , comprising:a metallic electrode portion, anda flux portion adjacent to the metallic electrode portion,wherein at least, one of said metallic electrode portion and flux portion contains at least one of lithium aluminate and lithium zirconate, and at least one of magnesium oxide and cerium oxide, andwherein the flux, portion contains both lithium aluminate and magnesium oxide, andwherein the flux portion contains about 1 to about 15% by weight of lithium aluminate and magnesium oxide combined.32. A ...

Подробнее
Номер записи: 16
12-09-2013 дата публикации

METHOD AND DEVICE FOR GENERATIVELY PRODUCING AT LEAST ONE COMPONENT AREA

Номер: US20130233846A1
Автор: Hanrieder Herbert, Jakimov Andreas, MEINERS WILHELM
Принадлежит:

Disclosed is a method for generatively producing or for repairing at least one area of a component, wherein a zone arranged downstream of a molten bath is post-heated to a post-heating temperature and the component is set to a base temperature, and also a device for carrying out such a method. 110.-. (canceled)11231. A method for generatively producing of for repairing at least one area of a component which is made up of individual powder layers , wherein the method comprises (i) locally heating , by a first high-energy beam , a powder layer to be produced to a melting temperature (T) , whereby a molten bath is formed , (ii) post-heating , by a second high-energy beam , a zone arranged downstream of the molten bath to a post-heating temperature (T) , and (iii) setting , by a heating device , a temperature of the component globally to a base temperature (T).121. The method of claim 11 , wherein the base temperature (T) is kept at a constant level.1312. The method of claim 12 , wherein the base temperature (T) is kept in a range of between 300° C. and 400° C. below the melting temperature (T).14. The method of claim 11 , wherein the component is heated virtually uniformly over its entire surface area.15. The method of claim 14 , wherein the component is heated inductively.16. The method of claim 11 , wherein the zone arranged downstream of the molten bath adjoins the molten bath.17. The method of claim 11 , wherein an environment surrounding the heating device is cooled.18. The method of claim 11 , wherein the first high-energy beam is a laser beam.19. The method of claim 11 , wherein the first high-energy beam is an electron beam.20. The method of claim 11 , wherein the second high-energy beam is a laser beam.21. The method of claim 11 , wherein the second high-energy beam is an electron beam.22. The method of claim 11 , wherein the second high-energy beam is an IR beam.23231. An apparatus for carrying out the method of claim 11 , wherein the apparatus comprises (a) ...

Подробнее
Номер записи: 17
19-09-2013 дата публикации

Compositions Comprising Placental Collagen for Use in Wound Healing

Номер: US20130245528A1
Автор: Harrell Carl Randall
Принадлежит:

Provided herein is a topical wound dressing that comprises a collagen and a flexible paste. Also provided is a wound dressing with a first layer of a sterilized mixture of collagen and a second adhesive layer effective to adhere to surrounding skin and to keep the first layer in contact with the wound. In addition there is provided a wound dressing foil that comprises collagen and a plastic compound that can provide a foil shape. Furthermore, methods of dressing wounds utilizing the wound dressings and wound dressing foil are provided herein. 1. A topical wound dressing , comprising:collagen and a flexible solid paste.2. The wound dressing of claim 1 , wherein the collagen comprises Type I and Type III collagen.3. The wound dressing of claim 2 , wherein the ratio of Type III collagen to Type I collagen is equal to or greater than about 50:50.4. The wound dressing of claim 1 , wherein the collagen is human collagen or placental collagen.5. The wound dressing of claim 1 , wherein the flexible solid paste is zinc oxide.6. A method for dressing a wound in a subject claim 1 , comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'applying the wound dressing of to the wound; and'}covering the wound dressing with a barrier layer, thereby dressing the wound in the subject.7. A wound dressing foil claim 1 , comprising:collagen; anda plastic compound that is effective to provide a foil shape that is adherable to the wound.8. The wound dressing foil of claim 7 , wherein the collagen is human collagen or placental collagen.9. The wound dressing foil of claim 7 , wherein the plastic compound is permeable to oxygen and other gases and impermeable to water in the wound.10. A method for dressing burn wounds in a subject claim 7 , comprising the step of:{'claim-ref': {'@idref': 'CLM-00007', 'claim 7'}, 'applying the wound dressing foil of to the burn wound such that the plastic compound comprising the foil adheres thereto, thereby dressing the burn wound in the ...

Подробнее
Номер записи: 18
26-09-2013 дата публикации

TREATMENT OF CHRONIC ULCEROUS SKIN LESIONS

Номер: US20130251665A1
Автор: Munro Hugh Semple
Принадлежит: FIRST WATER LIMITED

The invention provides a method of treating a wound (for example, a chronic ulcerous skin lesion) in a human or non-human mammal (particularly a human). The wound is contacted with a topical hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups, optionally with multiple pendant carboxylic groups, on each polymer molecule. 1. A method of treating pain and promoting healing of a chronic ulcerous skin lesion in a human or non-human mammal , comprising applying to the chronic ulcerous skin lesion as a topical dressing a hydrogel composition comprising a hydrophilic polymer carrying multiple pendant sulphonyl groups , optionally with multiple pendant carboxylic groups , on each polymer molecule , wherein at least some of the pendant sulphonyl are present in salt form , sodium and potassium countercations being present in the hydrogel associated with the pendant groups , and wherein the molar ratio of the sodium ions to potassium ions in the hydrogel is in the range of between about 100:1 and about 100:10.2. The method of claim 1 , wherein the hydrophilic polymer comprises 2-acrylamido-2-methylpropane sulfonic acid.3. The method of claim 2 , wherein the hydrophilic polymer is a crosslinked co-polymer of (3-Sulfopropyl)-acrylate and 2-acrylamido-2-methylpropane sulfonic acid. This application is a continuation of U.S. patent application Ser. No. 13/295,639 filed Nov. 14, 2011, which is a continuation of U.S. application Ser. No. 11/995,615 filed Aug. 4, 2008, now abandoned, which is a U.S. National Stage Entry Application under U.S.C. §371 of International Application No. PCT/GB2006/002632 filed on Jul. 14, 2006, which designated the U.S., and which claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 60/699,449 filed on Jul. 14, 2005, and also claims the benefit of United Kingdom Applications No. 0514526.3 filed Jul. 14, 2005; No. 0522530.5 filed Nov. 3, 2005; No. 0609827.1 filed May 17, 2006; and No. ...

Подробнее
Номер записи: 19
26-09-2013 дата публикации

METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY

Номер: US20130253003A1
Автор: GREGORY Jefferson J., NORDSIEK Michael T.
Принадлежит: MEDICIS PHARMACEUTICAL CORPORATION

Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”). 1. A method of topical and/or transdermal administration of imiquimod for treating a dermatological disorder in a mammal , which method comprises:(a) applying an effective amount of a formulation containing imiquimod on the skin of a mammal once a day at least 3 times a week on 3 different days for between about 8 consecutive weeks and 12 consecutive weeks, not exceeding 12 consecutive weeks; and(b) allowing said imiquimod to remain in contact with the skin for a sufficient time following said application to permit an effective amount of the imiquimod to penetrate the skin to achieve the antiviral effect.2. The method of claim 1 , wherein said formulation is applied for a duration of not more than one of the group consisting of: 8 weeks claim 1 , 9 weeks claim 1 , 10 weeks claim 1 , 11 weeks claim 1 , and 12 weeks.3. The method of claim 1 , wherein the formulation is applied once a day for at a frequency selected from the group consisting of: 4 times a week claim 1 , 5 times a week claim 1 , 6 times a week claim 1 , and every day of the week.4. The method of claim 1 , wherein the formulation contains an amount of imiquimod selected from the group consisting of: about 1% claim 1 , about 1.25% claim 1 , about 1.5% claim 1 , about 1.75% claim 1 , about 2% claim 1 , about 2.25% claim 1 , about 2.5% claim 1 , about 2.75% claim 1 , about 3% claim 1 , about 3.25% claim 1 , about 3.5% claim 1 , about 3.75% claim 1 , about 4% claim 1 , about 4.25% claim 1 , about 4.5% ...

Подробнее
Номер записи: 20
03-10-2013 дата публикации

Anodized inserts for coulomb damping or frictional damping

Номер: US20130256143A1
Автор: James G. Schroth, Mark W. Verbrugge
Принадлежит: GM GLOBAL TECHNOLOGY OPERATIONS LLC

A method comprising providing an insert having a portion capable of being oxidized and electrochemically anodizing the portion capable of being oxidized to provide a layer comprising an oxidized material thereon.

Подробнее
Номер записи: 21
10-10-2013 дата публикации

METHOD FOR TREATMENT OF ACNE USING PHARMACEUTICAL COMPOSITIONS OF CLINDAMYCIN

Номер: US20130266654A1
Автор: Kothari Jay Shantilal, Mittal Ravindra, Pancholi Jinesh Suresh, Patel Jitendra Dasharathlal, Roy Sunilendu Bhushan, Sheikh Shafiq
Принадлежит: CADILA HEALTHCARE LIMITED

The present invention relates to a method for treating, reducing or preventing acne. In particular, the present invention relates to methods for reducing the total number, incidence and severity of acne lesions on the skin which includes both inflammatory and non-inflammatory lesions. Further, the invention relates to reducing the incidence and severity of adverse events resulting from topical application of anti-acne agents resulting in improvement of skin tone. The method includes administering a novel and stable topical anti-acne pharmaceutical composition. 1. A method for treating acne , the method comprising administering a topical pharmaceutical composition comprising nano size droplets of clindamycin or salts thereof.2. A method for reducing total number of acne lesions on the skin , the method comprising administering a topical pharmaceutical composition comprising nano size droplets of clindamycin or salts thereof.3. The method as claimed in claim 2 , wherein the acne lesions are inflammatory lesions.4. The method as claimed in claim 2 , wherein the acne lesions are non-inflammatory lesions.5. A method for reducing the incidence and severity of acne lesions on the skin claim 2 , the method comprising administering a topical pharmaceutical composition comprising nano size droplets of clindamycin or salts thereof.6. The method as claimed in claim 5 , wherein the acne lesions are inflammatory lesions.7. The method as claimed in claim 5 , wherein the acne lesions are non-inflammatory lesions.8. The method as claimed in claim 1 , wherein the nano size droplets of clindamycin or a salt thereof have a particle size (D) of about 500 nm or less.9. The method as claimed in claim 1 , wherein the nano size droplets of clindamycin or a salt thereof have a particle size (D) of about 250 nm or less.10. The method as claimed in claim 1 , wherein the nano size droplets of clindamycin or salt thereof have a particle size (D) of about 100 nm or less.11. The method as claimed ...

Подробнее
Номер записи: 22
17-10-2013 дата публикации

BRAKE CALLIPER FOR A VEHICLE BRAKE SYSTEM AND METHOD AND DEVICE FOR PRODUCING A BRAKE CALLIPER

Номер: US20130270048A1
Автор: Schwarz Guenther, Wiltsch Dieter
Принадлежит: ROBERT BOSCH GMBH

A brake calliper for a vehicle brake system includes a housing produced in the form of a casting. At least one guide structure configured to receive a corresponding brake piston is provided in the housing. A method and a device are configured to produce a casting having at least one guide structure. The at least one guide structure is formed in the housing by at least one prefabricated insert having a defined production quality, which is encapsulated by the casting material of the housing. 1. A brake calliper for a vehicle brake system , comprising:a housing produced as a casting, andat least one guide structure provided in the housing, the at least one guide structure being configured to accommodate a corresponding brake piston,wherein the at least one guide structure in the housing is formed by at least one prefabricated insert with a defined production quality, the at least one prefabricated insert being encapsulated by the cast material of the housing.2. The brake calliper as claimed in claim 1 , wherein the at least one prefabricated insert is configured as one or more of a cylindrical bush and a deep-drawn sleeve.3. The brake calliper as claimed in claim 2 , wherein a brake line is secured on the bottom of the insert prefabricated as a deep-drawn sleeve claim 2 , said brake line being connected to a cavity of the deep-drawn sleeve.4. The brake calliper as claimed in claim 1 , wherein at least two guide structures are provided in the housing claim 1 , the at least two guide structures being arranged coaxially with one another at a defined spacing in opposite housing parts of the housing.5. A method for producing a casting with at least one guide structure claim 1 , comprising:introducing at least one guide structure with a defined production quality into a casting by way of at least one prefabricated insert,positioning the at least one insert in a casting tool using at least one positioning mechanism,filling the remaining cavities within the casting tool with a ...

Подробнее
Номер записи: 23
17-10-2013 дата публикации

TRANSDERMAL DRUG ADMINISTRATION DEVICE

Номер: US20130273119A1
Автор: Bredenberg Susanne, Dahlgren Anna, Engqvist Hakan, Lundqvist Thomas, PETTERSSON ANDERS, Sagstrom Anders
Принадлежит: OREXO AB

A transdermal drug administration device comprising a drug delivery element () defining a contact surface () for location, in use, against a patient's skin. The drug delivery element () includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material. 1. A transdermal drug administration device comprising a drug delivery element defining a contact surface for location , in use , against a patient's skin , the drug delivery element including a sustained-release pharmaceutical composition comprising an active pharmaceutical ingredient co-formedly interspersed within pores of a solid , continuous network comprising a carrier material and possessing a high mechanical strength.2. A transdermal drug administration device according to wherein the carrier material is based on one or more ceramic materials.3. A transdermal drug administration device according to wherein the ceramic material is an aluminium silicate or a calcium aluminate.4. A transdermal drug administration device according to wherein the ceramic material is a halloysite.5. A transdermal drug administration device according to wherein the carrier material is based on one or more geopolymeric materials.6. A transdermal drug administration device according to wherein the drug delivery element is formed from pellets of the composition embedded in a patch matrix.7. A transdermal drug administration device according to any of wherein the drug delivery element is formed from particles of the composition embedded in a patch matrix.8. A transdermal drug administration device according to wherein the composition further includes a pelletisation aid material.9. A transdermal drug administration device according to wherein the pelletisation aid material is ...

Подробнее
Номер записи: 24
17-10-2013 дата публикации

METHOD OF TREATING ACNE

Номер: US20130273187A1
Автор: Redkin Viktor Vladimirovich
Принадлежит:

The invention relates to methods of treating acne, which methods comprise topical administering to a skin of a subject in need thereof an effective amount of a lysate of preferably strains R/3.88, L/1.89, or mixture thereof. 1Actinomyces.. A method of treating acne , which comprises a step of topical administering to a skin of a subject in need thereof an effective amount of a lysate of2Actinomyces. The method of claim 1 , wherein said is selected from the group consisting of strains R/3.88 claim 1 , L/1.89 claim 1 , or mixture thereof. The present invention relates to medicine, particularly to a method of treating acne with lysate ofAcne is a widely distributed disease of a human skin. is a class of bacteria. USSR Patent No. 81396 (priority date of Sep. 27, 1948) describes a method of preparing lysate of and the use of the lysate for diagnostics and treating actinomycosis in humans with subcutaneous and intramuscular injections. USSR Patent No. 584952 (priority date of Jul. 7, 1988) describes a method of preparing lysate of purified from high molecular weight fractions 15000-25000 Daltons. Guideline for physicians “The use of Actinolysate in clinical practice” (Moscow, 2005) describes the use of injections of lysate of (Actinolysate) for the treatment of skin diseases, including abrasions, abscesses, cellulitis, acne, purulent fistulas, sores, pressure sores, hidradenitis, the lungs and liver abscess, peritonitis, cystitis, prostatitis, bacterial vaginitis, purulent mastitis, for the treatment of actinomycosis cervical-facial, skin and soft tissues, bone structure, internal organs, adrectal and genital areas, and for the treatment of purulent sinusitis, a bacterial tonsillitis, purulent otitis media, lymphadenopathy, for the treatment of odontogenic inflammation, chronic osteomyelitis, purulent bursitis purulent bacterial infections. Thus, the treatment of acne with lysates of is known from the art. However, only injections of lysates of were used for the treatment ...

Подробнее
Номер записи: 25
17-10-2013 дата публикации

Methods and Compositions for Treatment of Dermal Conditions

Номер: US20130274341A1
Автор: Gibbins Bruce L., Maley Joseph C.
Принадлежит:

The present invention comprises methods and compositions for the treatment of pathological conditions of the dermis and dermal structures of animals and humans. In particular, the present invention comprises the use of topical delivery vehicles, including hydrogels, which incorporate active agents such as organic acids, for the treatment of dermal conditions. 117-. (canceled)18. A composition for treatment of dermal structures , comprising ,a) a cross-linked polyacrylamide matrix, a non-gellable polysaccharide, citric acid, and water.19. The composition of claim 18 , wherein the citric acid is in a concentration of 8% to 16% w/w.20. The composition of claim 18 , wherein the water content is from 0.1% to 50%.21. A method of treating a dermal condition comprising claim 18 ,a) applying to a dermal structure a composition comprising a hydrophilic polymer matrix, at least one active agent, and at least one humectant, wherein the composition has a moisture content ranging from about 0.1% to 50% to create a diffusion gradient from the composition to the dermal structure, wherein the hydrophilic polymer matrix directly contacts the dermal structure, wherein moisture and the at least one active agent are transferred by the diffusion gradient from the hydrophilic polymer matrix composition to the dermal structure; andb) maintaining the composition at the dermal structure site for a sufficient amount of time so that an effective amount of the active agent is delivered.22. The method of claim 21 , wherein the dermal condition is an ungual condition and the dermal structure is an ungual structure.23. The method of claim 21 , wherein the hydrophilic polymer matrix includes a cross-linked polyacrylamide.24. The method of claim 21 , wherein the at least one active agent comprises an organic acid.25. The method of claim 24 , wherein the organic acid comprises citric acid.26. The method of wherein the citric acid is in a concentration between 0.1% w/w and 16% w/w.27. The method of ...

Подробнее
Номер записи: 26
31-10-2013 дата публикации

ANTIMICROBIAL SOLUTIONS AND METHODS

Номер: US20130287865A1
Автор: Bickerstaff Richard D., Code Kenneth R., Provenzano Joseph
Принадлежит: BIOLARGO LIFE TECHNOLOGIES, INC.

Antimicrobial solutions and delivery systems for them use liquid antimicrobial solutions with: at least 80% of total weight of a carrier liquid comprising water, alcohol or a mixture of water and alcohol; at least 0.0001% by weight of the solution of I; at least 0.0001% by weight of CuSO; and sufficient acid in the solution top provide a pH of less than 7.0. A buffering system is also preferable in the solution, and the solution may be provided directly to wounds, burns or other skin damage as a liquid, as a spray or as a gel. 1. A method of treating a wound or burn on tissue comprising applying an antimicrobial composition to the wound or burn on tissue , the antimicrobial composition comprising: at least 80% of total weight of a carrier liquid comprising water , alcohol , aqueous gel or a mixture of water and alcohol , water and aqueous gel , alcohol and aqueous gel , or water and alcohol and aqueous gel; at least 0.001% by weight of the solution of I; and sufficient acid in the solution to provide a pH of less than 6.9.2. The method of wherein the acid is sufficient in an amount to provide a pH of from 5.5 to 6.7; and the solution further comprising an inorganic cation and Iand at least 0.005% by weight of CuSO.3. The method of wherein the acid comprises a sulfamic acid compound.4. The method of wherein the acid comprises a sulfamic acid compound having the formula: NRSOH claim 1 , wherein R is independently selected from the group consisting of hydrogen and electron-withdrawing groups.5. The method of wherein the acid comprises a sulfamic acid compound having the formula: NRSOH claim 1 , wherein R is independently selected from the group consisting of hydrogen claim 1 , halogen claim 1 , cyano claim 1 , C1-C6 alkyl claim 1 , C1 to C6 substituted alkyl claim 1 , perhalo alkyl claim 1 , halosubstituted alkyl claim 1 , and electron-withdrawing groups.6. The method of wherein at least one R is hydrogen.7. The method of wherein exactly one R is hydrogen.8. A method ...

Подробнее
Номер записи: 27
31-10-2013 дата публикации

Pharmaceutical Compositions for Topical Delivery of Photosensitizers and Uses Thereof

Номер: US20130289089A1
Автор: Hunt David W.C., Morris Jerome A., Utkhede Deepank
Принадлежит:

The invention includes and provides compositions comprising photosensitizing agents, in particular lemuteporfin, and their use in photo-dynamic therapy for the treatment of dermatological conditions. 2. The composition of claim 1 , wherein said photosensitizer is present at a concentration in the range of about 0.01% to about 1.0%.3. The composition of claim 2 , wherein said photosensitizer is present at a concentration in the range of about 0.025% to about 0.5%.4. The composition of claim 3 , wherein said photosensitizer is present at a concentration in the range of about 0.1% to about 0.2%.5. The composition of claim 1 , wherein said excipient component comprises benzyl alcohol at a concentration in the range of about 1% to about 20%.6. The composition of claim 5 , wherein said benzyl alcohol concentration is about 10%.7. The composition of claim 1 , wherein said excipient component comprises diethylene glycol monoethyl ether (DGME) at a concentration in the range of about 5% to about 50%.8. The composition of claim 7 , wherein said excipient DGME concentration is in the range of about 15% to about 35%.9. The composition of claim 1 , wherein said excipient component comprises isopropyl alcohol at a concentration in the range of 40 to 70%.10. The composition of claim 1 , wherein said photosensitizer is a green porphyrin.11. The composition of claim 10 , wherein said green poprhyrin is lemuteporfin.12. A topical formulation effective for localizing a photosensitizer to a sebaceous gland comprising:(a) a photosensitizing component comprising a photosensitizer; and associated therewith but separate therefrom,(b) an excipient component;wherein said photosensitizer is present in an amount sufficient to form, on mixing, a supersaturated solution thereof once components (a) and (b) are mixed.13. A topical formulation of for use in a method of treating acne in a subject in need thereof claim 1 , comprising applying a therapeutically effective amount of said composition to ...

Подробнее
Номер записи: 28
07-11-2013 дата публикации

COMPOSITION FOR THE TRANSDERMAL DELIVERY OF FENTANYL

Номер: US20130295158A1
Автор: Cantor Adam S., Ocheltree Terrance W., Robles Cynthia A.
Принадлежит:

A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl. 1. A transdermal patch for administering fentanyl through the skin comprising:(a) a backing layer; and(b) a polyacrylate adhesive reservoir disposed on the backing layer, at least the skin contacting surface of said reservoir being adhesive; comprising a single phase polymeric composition free of undissolved fentanyl and containing an amount of fentanyl sufficient to induce and maintain analgesia in a human for at least three days.2. The patch of wherein the reservoir contains fentanyl and the patch has an area of about 5 cmto about 100 cm.3. The patch of wherein the reservoir contains fentanyl and the patch has an area of about 5 cmto about 100 cmand contains no permeation enhancer.4. The patch of wherein the reservoir contains fentanyl and the patch has an area of about 1 cmto about 40 cm.5. The patch of wherein said reservoir comprises an amount of dissolved fentanyl sufficient to induce and maintain analgesia for 4 to 7 days.6. The patch of wherein said reservoir comprises a composition having a solubility for fentanyl of about 1 weight % to at least about 30 weight %.7. The patch of wherein the reservoir further comprises an enhancer.8. The patch of wherein the backing layer comprises a polymer selected from the group consisting of polyurethane claim 1 , polyethylene claim 1 , polyethylene terephthalate (PET) claim 1 , and PET polyolefin laminates.9. The patch according to wherein the polyacrylate adhesive comprises one or more monomer components selected from the group consisting of butyl acrylate claim 1 , butyl methacrylate claim 1 , hexyl acrylate claim 1 , hexyl methacrylate claim 1 , ...

Подробнее
Номер записи: 29
28-11-2013 дата публикации

TRANSDERMAL DELIVERY SYSTEM

Номер: US20130317122A1
Автор: Setiawan Kerrie, Watkinson Adam
Принадлежит: Acrux DDS Pty Ltd.

A transdermal delivery system comprising a composition comprising a physiologically active agent and a penetration enhancer wherein the penetration enhancer comprises a combination of (i) an ester of salicylic acid, preferably selected from the Cto Caliphatic ester of salicylic acid and (ii) polyethylene glycol (PEG) of average molecular weight no more than 300. 122.-. (canceled)23. A transdermal delivery system comprising a composition comprising a physiologically active agent and a penetration enhancer wherein the penetration enhancer comprises a combination of (i) a C6 to C30 aliphatic ester of salicylic acid and (ii) polyethylene glycol (PEG) of average molecular weight no more than 300.24. A transdermal delivery system according to claim 23 , wherein the ester of salicylic acid is a C6 to C12 alkyl ester.25. A transdermal delivery system according to claim 23 , wherein the ester of salicylic acid is the ethylhexyl ester.26. A transdermal delivery system according to claim 23 , wherein the ester of salicylic acid is present in an amount of from 0.1 to 10% by weight of the total transdermal composition.27. A transdermal delivery system according to claim 23 , wherein the PEG of average molecular weight of no more than 300 is present in an amount in the range of from 0.1 to 40% by weight of the total composition.28. A transdermal delivery system according to claim 23 , wherein the weight ratio of ester of salicylic acid to polyethylene glycol of average molecular weight no more than 300 is in the range of from to 1:10 to 10:1.29. A transdermal delivery system according to claim 23 , wherein the composition comprises a volatile solvent selected from C2 to C4 alkanol.30. A transdermal delivery system according to claim 23 , wherein the volatile solvent is present in the composition in an amount in the range of from 70% to 95% by weight of the total composition.31. A transdermal delivery system according to claim 23 , wherein the composition consists essentially of:( ...

Подробнее
Номер записи: 30
05-12-2013 дата публикации

LASER CLADDING DEVICE WITH AN IMPROVED NOZZLE

Номер: US20130319325A1
Автор: Hageniers Omer Leon, Whitfield Ronald Peter
Принадлежит:

A laser cladding device for applying a coating to a part comprising a laser which can generate laser light, which is adapted to heat the coating and the part, a main body defining a laser light channel adapted to transmit the laser light to the part, a coating channel adapted to transmit the coating to the part, and a vacuum channel and a nozzle having an exit. The nozzle comprises a delivery port at one end of the laser light channel, a coating port at one end of the coating channel, and a vacuum port at one end of the vacuum channel, wherein the vacuum port is positioned generally adjacent the delivery port In operation the vacuum port draws a vacuum, pulling the coating towards the part. 1. A laser cladding device for applying a coating to a part , comprising:a laser configured to generate laser light;a nozzle assembly defining: (i) a coating channel configured to transmit the coating to the part, (ii) a coating port at one end of the coating channel, (iii) a vacuum channel, and (iv) a vacuum port at one end of the vacuum channel, wherein the vacuum port is positioned generally adjacent the coating port and in operation the vacuum port draws a vacuum;a zoom lens assembly configured to receive the laser light and transmit the laser light to the part, wherein the laser light heats the coating and the part in a laser work zone; anda controller configured to adjust the zoom lens assembly such that a size of the laser work zone is variable.2. The laser cladding device of claim 1 , wherein the nozzle assembly is a lateral feed nozzle assembly.3. The laser cladding device of claim 1 , wherein the nozzle assembly further defines (i) a shaping gas channel claim 1 , and (ii) a shaping gas port at one end of the shaping gas channel claim 1 , the shaping gas channel configured to transmit shaping gas from the nozzle assembly.4. The laser cladding device of claim 3 , wherein the shaping gas channel claim 3 , the coating channel and the vacuum channel each have a tubular ...

Подробнее
Номер записи: 31
06-02-2014 дата публикации

TRANSDERMAL FORMULATION CONTAINING COX INHIBITORS

Номер: US20140039028A1
Автор: Mikulásik Endre, Spaits Tamás, SZAKÁLYNÉ SINKA Ágota
Принадлежит: EGIS PHARMACEUTICALS PLC

Disclosed are gel compositions suitable for the topical administration of an active compound having poor solubility and skin penetration, for example, of a COX-2 inhibitor compounds, processes of preparation thereof and methods of use thereof for the treatment of indications treatable by the active compound. 1. A pharmaceutical composition , comprising:a selective COX-2 inhibitor, forming a plurality of solid particle;at least one solubilizer;a wetting agent;a gel forming agent;a solvent comprising water; andat least one volatile siloxane agent coating the selective COX-2 inhibitor,wherein the solid particles are dispersed in the composition, andwherein the composition comprises a suspension gel.2. The composition of claim 1 , wherein the solubilizer comprises polyethylene glycol hexadecyl ether.3. The composition of claim 2 , wherein the polyethylene glycol hexadecyl ether comprises about 5-10% of the composition.4. The composition of claim 1 , wherein the solubilizer comprises poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene) glycol.5. The composition of claim 4 , wherein the poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene) glycol comprises about 5-10% of the composition.6. The composition of claim 1 , wherein the solubilizer comprises at least one of polyethylene glycol hexadecyl ether claim 1 , poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene) glycol claim 1 , polyethylene glycol 1000 claim 1 , polyoxyethylene (20) sorbitan monostearate claim 1 , span 60 claim 1 , and emulsifier 10.7. The composition of claim 1 , wherein the solubilizer comprises polyethylene glycol hexadecyl ether and polyethylene glycol 1000.8. The composition of claim 1 , wherein the wetting agent comprises polyethylene glycol.9. The composition of claim 1 , wherein the gel forming agent comprises polymerized prop-2-enoic acid ester.10. The composition of claim 9 , wherein the polymerized prop-2-enoic acid ester comprises ...

Подробнее
Номер записи: 32
20-02-2014 дата публикации

HOT-WIRE CONSUMABLE WITH EMBEDDED ID TAG

Номер: US20140048524A1
Автор: ASH Elliott, Matthews William T.
Принадлежит: LINCOLN GLOBAL, INC.

A system and method for using filler wire with embedded information is provided. The filler wire includes a sheath comprising a first filler material and a core that is defined by the sheath. The core includes a second filler material and at least one integrated circuit module. The at least one integrated circuit module includes at least information about the filler wire. In some embodiments, the at least one integrated circuit module is configured for at least one of read operations and write operations that are done using a remote device. 1. A filler wire with embedded information , said filler wire comprising:a sheath comprising a first filler material; anda core defined by said sheath and comprising a second filler material and at least one integrated circuit module,wherein said at least one integrated circuit module comprises at least information about said filler wire.2. The filler wire of claim 1 , wherein said at least one integrated circuit module is configured for at least one of read operations and write operations that are done using a remote device.3. The filler wire of claim 2 , wherein said at least one integrated circuit module is an RFID device.4. The filler wire of claim 1 , wherein said filler wire information comprises at least one of filler wire type claim 1 , manufacturer claim 1 , production number claim 1 , and date of manufacture.5. The filler wire of claim 1 , wherein said integrated circuit is configured to store information about a process in which said filler wire is used claim 1 ,wherein said process information comprises at least one of type of said process, operator ID, date of said process, time of said process, temperature of molten puddle, and rate of cooling of said molten puddle.6. The filler wire of claim 1 , wherein said at least one integrated circuit module has an outer shape that is one of spherical claim 1 , elliptical and oval.7. The filler wire of claim 1 , wherein said at least one integrated circuit module comprises an ...

Подробнее
Номер записи: 33
06-03-2014 дата публикации

SYSTEMS AND METHODS FOR WELDING ELECTRODES

Номер: US20140061179A1
Автор: Amata Mario, Barhorst Steven, Pagano Kevin
Принадлежит: Hobart Brothers Company

The invention relates generally to welding and, more specifically, to welding wires for arc welding, such as Gas Metal Arc Welding (GMAW) or Flux Core Arc Welding (FCAW). In one embodiment, a method of manufacturing a tubular welding wire includes disposing a core within a metallic sheath. Further, the core includes an organic stabilizer component, in which the organic stabilizer component is an alkali metal or alkali earth metal salt of an organic molecule or an organic polymer. 1. A method of manufacturing a tubular welding wire , comprising:disposing a core within a metallic sheath, wherein the core comprises an organic stabilizer component, wherein the organic stabilizer component is an alkali metal or alkali earth metal salt of an organic molecule or an organic polymer.2. The method of claim 1 , wherein the organic stabilizer component comprises between approximately 0.01% and approximately 5% of the tubular welding wire by weight.3. The method of claim 1 , wherein the organic stabilizer component comprises a sodium or potassium salt of carboxymethyl cellulose.4. The method of claim 1 , wherein the core comprises a rare earth component comprises between approximately 0.01% and approximately 5% of the tubular welding wire by weight.5. The method of claim 1 , wherein the core comprises a carbon component comprising between approximately 0.01% and approximately 5% of the tubular welding wire by weight.6. The method of claim 1 , wherein the core comprises an agglomerate comprising oxides of each of sodium or potassium claim 1 , titanium claim 1 , and manganese claim 1 , and wherein the agglomerate comprises between approximately 0.01% and approximately 5% of the tubular welding wire by weight.7. The method of claim 1 , wherein the core comprises between approximately 7% and approximately 40% of the tubular welding wire by weight.8. The method of claim 1 , wherein the tubular welding wire has an outer diameter between approximately 0.024 in and approximately 0.062 ...

Подробнее
Номер записи: 34
13-03-2014 дата публикации

MEDICINAL PREPARATION "RENESSANS" HAVING AN ANTIBACTERIAL, ANTI-ULCEROUS AND IMMUNO-MODULATING ACTION

Номер: US20140072598A1
Автор: Begaliev Shokan Sabirkhanovich, Nugerbekova Kulshat Magzumovna
Принадлежит:

The invention relates to the field of medicine, particularly to medical preparations of anti-bacterial, anti-ulcer and immune simulating effects, which can be used in injection form. The medical preparation “RENESSANS” contains components in the following ratio (wt %): 2. The medical preparation of claim 1 , characterized in that the medical preparation is intended for intravenous claim 1 , intramuscular or oral administration to a patient in a pharmaceutically effective amount.3. The medical preparation of claim 1 , the use of the medical preparation being for treatment of viral and bacterial infections of mammals claim 1 , including humans.4. The medical preparation of claim 1 , the use of the medical preparation being for treatment of peptic ulcer disease of mammals claim 1 , including humans.5. The medical preparation of claim 1 , the use of the medical preparation being for increasing immunity of mammals claim 1 , including humans. This application claims the benefit of the priority filing date of PCT application no. PCT/KZ2011/000018 filed on Nov. 10, 2011 and published in WO2012/158002 on Nov. 22, 2012. The earliest priority filing date claimed is May 16, 2011.Not ApplicableNot ApplicableThe invention relates to the pharmaceutical industry, in particular, iodine-containing pharmaceuticals.Nowadays iodine medications occupy an important place among modern antiseptics. Many infections are caused by agents that are sensitive to iodine-containing medications which exhibit fungicidal, cellulicidal and antiprotozoal actions, and which act against some spores while not developing an acquired resistance to them.The problem of using iodine is that high concentrations are toxic, irritating the skin and mucous membranes. However, in combination with polysaccharides and polymers, iodine largely loses toxicity, and operates more slowly and continuously (during 5 hours), while maintaining anti-virus and anti-microbial properties (Nikulin V., V. Gerasimenko, 2008; E. ...

Подробнее
Номер записи: 35
27-03-2014 дата публикации

TOPICAL KETOPROFEN COMPOSITION

Номер: US20140088195A1
Автор: Buyuktimkin Nadir, Buyuktimkin Servet, Yeager James L.
Принадлежит: Achelios Therapeutics, Inc.

A topical composition, specifically an oil-in-water emulsion, comprised of ketoprofen and oxybenzone in a physiologically acceptable topical carrier. The composition is applied topically to alleviate pain, especially pain associated with migraine headache. The composition has good photostability as well as freeze/thaw stability. 1. A topical composition which is an oil-in-water emulsion and comprises , on a weight basis:{'sub': 2', '3, 'about 0.5 to about 15 percent ketoprofen, about 0.01 to about 1 percent of a chelating agent, about 0.15 to about 1.5 percent of a cross-linked polyacrylic acid interpolymer, about 0.15 to about 1.5 percent of a cross-linked polyacrylic acid homopolymer, about 2.5 to about 6 percent oxybenzone, about 0.25 to about 2.5 percent of a an emulsifying agent, about 5 to about 15 percent of a water-miscible alkylene glycol, about 10 to about 30 percent of a Cto Calkanol, about 0.5 to about 2.5 percent of a cosmetic preservative, about 0.02 to about 2 percent of an antioxidant, about 0.001 to about 0.1 percent of an emollient, a pH modifier in an amount sufficient to maintain a pH value of the composition in the range of about 4.5 to about 6, and the remainder water.'}2. The topical composition in accordance with wherein the oil-in-water emulsion has a cream-like consistency.3. The topical composition in accordance with and comprising:about 10 percent ketoprofen, about 0.05 percent disodium salt of ethylenediaminetetracetic acid, about 1.25 percent of a cross-linked polyacrylic acid interpolymer, about 0.5 percent of a cross-linked polyacrylic acid homopolymer, about 5 percent of oxybenzone, about 0.5 percent of PEG-40 hydrogenated castor oil, about 10 percent propylene glycol, about 10 percent of anhydrous ethanol, about 9 percent isopropanol, about 1 percent benzyl alcohol, about 0.05 percent Vitamin E, about 1 percent of butylated hydroxytoluene, about 3 percent isopropyl myristate, about 1.5 percent triethanolamine, and the rest water.4. ...

Подробнее
Номер записи: 36
01-01-2015 дата публикации

METHOD AND MACHINING DEVICE BY COMBINED ADDITION OF MATERIAL AND SHAPING

Номер: US20150000108A1
Автор: Carabin Gilles, Hascoet Jean-Yves, Mognol Pascal
Принадлежит:

A machining method and apparatus for machining a part comprises a machining head and motorized axes comprising a rotary axis for displacing the machining head in a working space. Apparatus comprises a mechanism for positioning a part and holding it in position the working space. The machining head comprises a support for supporting a material shaping tool and a supply device for supplying material. 117-. (canceled)18. Apparatus for machining a part , comprising:a machining head and motorized axes comprising a rotary axis for displacing the machining head in a working space;a mechanism for positioning and holding the part in position in the working space; andwherein the machining head comprises a support for supporting a material shaping tool and a supply device for supplying a material.191. A method implemented utilizing apparatus according to claim , comprising the steps of:depositing a layer of the material on the part using the supply device during an adding operation;shaping a section of the part using the material shaping tool during a shaping operation;wherein the adding and shaping operations are performed in a same machining phase along trajectories that extend in three dimensions of the working space; andwherein the supply device and the material shaping tool are directed normally in relation to the trajectories.20. Apparatus according to claim 18 , further comprising:a sensor located on the machining head; anda device for measuring, on the motorized axes, a position of the sensor in the working space.21. Apparatus according to claim 18 , wherein the material shaping tool is a cutting tool.22. Apparatus according to claim 21 , further comprising a tool for transmitting a cutting motion to the cutting tool.23. Apparatus according to claim 21 , further a tool for transmitting a cutting motion to the part.24. Apparatus according to claim 18 , wherein the material shaping tool is a tool for forming the material by plastic deformation.25. Apparatus according to ...

Подробнее
Номер записи: 37
05-01-2017 дата публикации

PERIPLANETA AMERICANA EXTRACT OR PERIPLANETA AMERICANA MEDICINAL POWDER AS WELL AS PREPARATION METHOD THEREOF AND APPLICATION IN PREPARATION FOR MEDICINE USED FOR PREVENTING AND TREATING RADIATION-INDUCED DAMAGES

Номер: US20170000829A1
Автор: Chen Guangjian, Geng Funeng
Принадлежит:

The present invention provides an application of a medicinal powder or a extract in preparation for a medicine used for preventing and treating radiation-induced damages. The medicine is capable of preventing and treating the damages caused by radiation therapy for nasopharyngeal cancer, esophageal cancer, stomach cancer, lung cancer, liver cancer, breast cancer, waldeyer's lymphoma, and other cancers. Through test verification, the medicine of the present invention has an obvious prevention and treatment effect for damages caused by radiation therapy for patients with breast tumours and breast cancer after surgery. 1periplaneta americanaperiplaneta americana. An application of a medicinal powder or a extract in preparation for a medicine used for preventing and treating radiation-induced damages.2periplaneta americanaperiplaneta americana. The application of the medicinal powder or the extract in preparation for the medicine used for preventing and treating radiation-induced damages according to claim 1 , characterized in that the medicine is capable of preventing and treating the damages caused by radiation therapy for one or a plurality of tumors of nasopharyngeal cancer claim 1 , esophageal cancer claim 1 , stomach cancer claim 1 , lung cancer claim 1 , liver cancer claim 1 , breast cancer and waldeyer's lymphoma.3periplaneta americanaperiplaneta americanaperiplaneta americanaperiplaneta americana. The application of the medicinal powder or the extract in preparation for the medicine used for preventing and treating radiation-induced damages according to claim 1 , characterized in that the medicine is a pharmaceutical preparation prepared by taking a extract or a medicinal powder as an active ingredient claim 1 , and adding pharmaceutically common auxiliary materials; the pharmaceutical preparation may be an oral preparation or an external preparation;the oral preparation comprises a liquid preparation, capsules, powder and tablets; andthe external preparation ...

Подробнее
Номер записи: 38
14-01-2021 дата публикации

Using Paper with Heightened KELEA to Enhance the Alternative Cellular Energy (ACE) Pathway

Номер: US20210008202A1
Автор: Martin William John
Принадлежит:

Placing paper onto the skin of an individual is used to support the alternative cellular energy (ACE) pathway in a human or animal subject. The benefits can be increased if the paper is first provided with a heightened level of KELEA by being stored for several hours in the vicinity of containers of KELEA activated water. KELEA is an abbreviation of “kinetic energy limiting electrostatic attraction.” The ACE pathway is a form of cellular energy, which is different from that provided by the calories in food or, in the case of plants and certain bacteria, by photosynthesis. In relative terms, the direct contact of the body with paper that has a heightened level of KELEA achieves better transfer of KELEA to living life forms than does the indirect exposure of the body to KELEA activated water contained in wearable waterceutical pouches. The direction of transfer of KELEA between the skin of an individual and paper can also be used to monitor the activity of the ACE pathway in the individual. Paper with heightened KELEA has numerous therapeutic and increased wellbeing applications in humans, animals, and plants. 1. A method of enhancing the alternative cellular energy (ACE) pathway in human and animal subjects , and thereby benefiting the subjects , comprising the placement onto the skin of the subject , a cellulose containing material in which part of the measured weight of the material is attributed to a heightened level of an attracted energy , which the Applicant refers to as KELEA , being an abbreviation for kinetic energy limiting electrostatic attraction; the placement of the material being for a sufficient time to allow for the transfer of KELEA to the subject , resulting in a lowering of the measured weight of the placed material and an improvement in the wellbeing of the subject.2. A method of quantitatively assessing the amounts of KELEA transfer to a subject from a cellulose containing material that has been applied directly onto the skin of the subject , ...

Подробнее
Номер записи: 39
10-01-2019 дата публикации

Composition For Enzymatic Debridement

Номер: US20190008927A1
Автор: HANSON Douglas Philip
Принадлежит:

Methods and compositions for the enzymatic debridement of wounds are provided. Methods for preparing enzymatic debridement compositions are also provided. In one embodiment, an enzymatic debridement composition prepared by dissolving crude bromelain in a composition comprising a weak acid, and filtering and/or dialyzing the dissolved crude bromelain to obtain the enzymatic debridement composition is provided. 110.-. (canceled)11. A method for debridement of devitalized tissue from a subject comprising:{'claim-ref': {'@idref': 'CLM-00021', 'claim 21'}, '(a) contacting devitalized tissue with an enzymatic debridement composition according to to dissolve the devitalized tissue; and'}(b) removing the dissolved devitalized tissue.12. The method of claim 11 , wherein the enzymatic debridement composition was prepared by(a) dissolving crude bromelain in a composition comprising a weak acid;(b) filtering the dissolved crude bromelain to obtain a filtered bromelain composition; and/or,(c) dialyzing the filtered bromelain composition to obtain the enzymatic debridement composition.13. The method of claim 11 , wherein the enzymatic debridement composition is in contact with the devitalized tissue for 1 to 48 hours before the dissolved devitalized tissue is removed.14. The method of claim 11 , wherein contacting the devitalized tissue is by coating the devitalized tissue with the enzymatic debridement composition or by injecting the enzymatic debridement composition into the devitalized tissue.15. The method of claim 11 , further comprising covering the devitalized tissue with a wound dressing.16. The method of claim 15 , wherein the wound dressing is gauze.17. (canceled)18. (canceled)19. The enzymatic debridement composition of claim 21 , wherein the enzymatic debridement composition is formulated as a gel claim 21 , foam claim 21 , or spray.20. The enzymatic debridement composition of claim 19 , wherein the gel comprises 10% by weight of the enzymatic debridement composition. ...

Подробнее
Номер записи: 40
18-01-2018 дата публикации

ANESTHETIC BANDAGE

Номер: US20180015050A1
Автор: Olivero Ana R.
Принадлежит:

A bandage for delivering an anesthetic through a patient's skin at the site of a hypodermic injection prior to the administration of the hypodermic injection to alleviate pain due to the injection. The bandage has a first layer having a perimeter area adhesive, an anesthetic delivery layer disposed on the first layer inside the perimeter area and containing an anesthetic for delivery into the patient's skin, a first peel-off layer covering the anesthetic delivery layer for keeping the anesthetic delivery layer sterile until the peel-off layer is removed, the first layer being placed on the skin of the patient at the future site of the injection with the anesthetic delivery layer and adhesive being in contact with the skin of the patient thereby to adhere the bandage to the site and allow the anesthetic delivery layer to deliver the anesthetic into the skin, wherein the anesthetic delivery layer comprises a material for accelerating the delivery of the anesthetic into the patient's skin, the anesthetic delivery layer adapted to receive the injection therethrough after the skin has undergone numbing by the anesthetic. 1. A bandage for delivering an anesthetic through a patient's skin at the site of a hypodermic injection prior to the administration of the hypodermic injection to alleviate pain due to the injection , comprising:a first layer having a perimeter area adhesive;an anesthetic delivery layer disposed on the first layer inside the perimeter area and containing an anesthetic for delivery into the patient's skin;a first peel-off layer covering the anesthetic delivery layer for keeping the anesthetic delivery layer sterile until the peel-off layer is removed;the first layer being placed on the skin of the patient at the future site of the injection with the anesthetic delivery layer and adhesive being in contact with the skin of the patient thereby to adhere the bandage to the site and allow the anesthetic delivery layer to deliver the anesthetic into the skin; ...

Подробнее
Номер записи: 41
21-01-2016 дата публикации

Topical Localized Isoxazoline Formulation

Номер: US20160015689A1
Автор: Fuchs Stefan, Heckeroth Anja Regina, Müller Ramona, Williams Heike, Zoller Hartmut
Принадлежит: Intervet Inc.

This invention provides topical localized formulations comprising an isoxazoline compound and a pharmaceutically or veterinary acceptable liquid carrier vehicle comprising N,N-diethyl-3-methylbenzamide as a solvent and an improved method for controlling, and preventing parasite infestation in animals. 3. The topical localized formulation according to claim 1 , wherein Ris H and Ris —CH—C(O)—NH—CH—CF claim 1 , —CH—C(O)—NH—CH—CH claim 1 , —CH—CH—CFor —CH—CF.4. The topical localized formulation according to claim 1 , wherein the formulation comprises 4-[5-(3 claim 1 ,5-Dichlorophenyl)-5-trifluoromethyl-4 claim 1 ,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2 claim 1 ,2 claim 1 ,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide.5. The topical localized formulation according to claim 1 , wherein the formulation comprises 1 to 50% N claim 1 ,N-diethyl-3-methylbenzamide.6. The topical localized formulation according to claim 1 , wherein the liquid carrier vehicle comprises N claim 1 ,N-diethyl-3-methylbenzamide as solvent and a co-solvent selected from the group consisting of dimethyl sulfoxide claim 1 , acetone claim 1 , dimethylacetamide claim 1 , ethyl alcohol claim 1 , eucalyptol claim 1 , dipropylene glycol monomethyl ether claim 1 , methylethyl ketone claim 1 , glycofurol claim 1 , ethyl-L-lactate claim 1 , and a mixture of at least two of these co-solvents.7. The topical localized formulation according to wherein the liquid carrier vehicle comprises N claim 1 ,N-diethyl-3-methylbenzamide as solvent and a mixture of at least two of acetone claim 1 , ethyl-L-lactate claim 1 , dimethyl sulfoxide claim 1 , dimethylacetamide and glycofurol.8. The topical localized formulation according to wherein there is a weight/weight ratio of the cosolvent/solvent in the spot-on composition and the weight/weight ratio of the cosolvent/solvent is between 4/1 and 1/5.9. The topical localized formulation according to claim 1 , wherein the formulation further comprises an effective amount of one or ...

Подробнее
Номер записи: 42
18-01-2018 дата публикации

THERAPEUTIC INTERVENTION GUIDANCE SYSTEM FOR ATOPIC ECZEMA AND A METHOD OF PROVIDING THERAPEUTIC INTERVENTION GUIDANCE

Номер: US20180015150A1
Автор: JEONG Sekyoo, KIM HyunJong, PARK Beyong Deog, PARK Kyungho, SHIN Kyong-Oh
Принадлежит:

A therapeutic intervention guidance system for atopic eczema includes a device measuring a skin surface moisture level and a Trans-Epidermal Water Loss (TEWL) value of a subject, a process comparing the skin surface moisture level and the TEWL value with a predetermined level and value, and an outcome providing a therapeutic intervention guidance based on the comparison. A method of providing therapeutic intervention guidance for atopic eczema includes measuring a skin surface moisture level and a Trans-Epidermal Water Loss (TEWL) value of a subject, comparing the skin surface moisture level and the TEWL value with a predetermined level and value, and providing a therapeutic intervention guidance based on the comparison. 1. A therapeutic intervention guidance system for atopic eczema comprising:a device measuring a skin surface moisture level and a Trans-Epidermal Water Loss (TEWL) value of a subject,a process comparing the skin surface moisture level and the TEWL value with a predetermined level and value, andan outcome providing a therapeutic intervention guidance based on the comparison.2. The therapeutic intervention guidance system of claim 1 , wherein the therapeutic intervention guidance includes usage of a topical calcineurin product.3. A method of providing therapeutic intervention guidance for atopic eczema comprising:measuring a skin surface moisture level and a Trans-Epidermal Water Loss (TEWL) value of a subject,comparing the skin surface moisture level and the TEWL value with a predetermined level and value, andproviding a therapeutic intervention guidance based on the comparison.4. The method of claim 3 , wherein the therapeutic intervention guidance includes usage of a topical calcineurin product.5. The method of claim 3 , wherein the therapeutic intervention guidance further includes stop using the topical calcineurin product.6. The method of claim 3 , wherein the therapeutic intervention guidance includes using a skin-care procedure.7. The method ...

Подробнее
Номер записи: 43
15-01-2015 дата публикации

FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDES

Номер: US20150018284A1
Автор: GHATNEKAR Gautam
Принадлежит:

This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided. 132-. (canceled)33. A topical formulation comprising at least one alpha connexin polypeptide and hydroxyethylcellulose gel , wherein the hydroxyethylcellulose gel stabilizes the alpha connexin polypeptide.34. The topical formulation of claim 33 , wherein the hydroxyethylcellulose gel stabilizes the alpha connexin polypeptide so that after 3 months of storage at 5° C. at least 98% of the alpha connexin polypeptide is detectable by analytical methods.35. The topical formulation of claim 33 , wherein the hydroxyethylcellulose gel stabilizes the alpha connexin polypeptide so that after 3 months of storage at 5° C. at least 95% of the alpha connexin polypeptide is detectable by analytical methods.36. The topical formulation of claim 33 , wherein the hydroxyethylcellulose is present at a concentration of about 1.25% (w/w).37. The topical formulation of claim 33 , wherein the at least one alpha connexin polypeptide is present at a concentration of between about 0.005% (w/w) and about 1.00% (w/w).38. The topical formulation of claim 33 , further comprising a buffering agent.39. The topical formulation of claim 38 , wherein the buffering agent maintains the pH of the topical formulation between about 5 and about 7.40. The topical formulation of claim 38 , wherein the buffering agent is a phosphate buffer.41. The topical ...

Подробнее
Номер записи: 44
21-01-2021 дата публикации

METHOD FOR LASER CLADDING AND FORMING OF METAL OR ALLOY UNDER PARTIAL ATMOSPHERE PROTECTION

Номер: US20210016393A1
Автор: FU Geyan, SHI Shihong, Shi Tuo, WU JIZHUO
Принадлежит: Zhangjiagang Institute of Industrial Technologies, Soochow University

The present invention relates to a method for laser cladding and forming of a metal or alloy under partial atmosphere protection. Including: transporting a metal or alloy powder beam by an inert carrier gas to move on a machined surface with a focused laser beam; and forming at least one layer of inert protective gas at the outer periphery of the metal or alloy powder beam. The inert protective gas includes first inert protective gas, and the first inert protective gas is at the outer periphery of the focused laser beam. The problems of limited size, high cost and difficulty in moving a cladding and forming system and the like during part forming are solved by forming the inert protective gas at the outer periphery of the focused laser beam. Compared with the prior art, the convenient, fast and economical method is provided for on-site part forming and repair. 110-. (canceled)11. A method for laser cladding and forming of a metal or alloy under partial atmosphere protection , comprising:transporting a metal or alloy powder beam by an inert carrier gas to move on a machined surface with a focused laser beam; andforming at least one layer of inert protective gas at the outer periphery of the metal or alloy powder beam.12. The method for laser cladding and forming of a metal or alloy under partial atmosphere protection according to claim 11 , wherein the metal or alloy powder beam and the inert carrier gas are coaxial with the focused laser beam claim 11 , and spraying directions thereof are consistent.13. The method for laser cladding and forming of a metal or alloy under partial atmosphere protection according to claim 11 , wherein the thickness of the inert protective gas of each layer is sequentially increased in the radial direction of a center line of the metal or alloy powder beam.14. The method for laser cladding and forming of a metal or alloy under partial atmosphere protection according to claim 11 , wherein the inert protective gas comprises first inert ...

Подробнее
Номер записи: 45
25-01-2018 дата публикации

STIMULATION OF APPETITE AND TREATMENT OF ANOREXIA IN DOGS AND CATS

Номер: US20180021251A1
Автор: Buhles William, Cortez Richard, Maas Kristin, Perez Daniel, Srivastava Geeta
Принадлежит: Kindred Biosciences, Inc.

Pharmaceutical formulations and methods useful for the treatment of anorexia and the stimulation of appetite and weight gain, and the management of weight loss in dogs and cats. 1. A pharmaceutical formulation for the treatment of anorexia and stimulation of appetite and management of weight loss in dogs and cats said formulation comprising a therapeutically effective dose of mirtazapine for topical administration by transdermal absorption.2. The pharmaceutical formulation of claim 1 , wherein said formulation is an ointment.3. The pharmaceutical formulation of or wherein at least one component of the formulation is a solubilizer.4. The pharmaceutical formulation of any one of to wherein at least one component is a penetration enhancer.5. The pharmaceutical formulation of any one of to that comprises both a penetration enhancer and solubilizer.6. The pharmaceutical formulation of that contains at least 25% by weight of said mixture of penetration enhancer and solubilizer.7. The pharmaceutical formulation of any one of to claim 5 , which is selected from the group consisting of Formulation G claim 5 , Formulation H incorporating Dry-Flo AF claim 5 , Formulation H incorporating Dry-Flo TS claim 5 , Formulation O claim 5 , Formulation T incorporating Dry-Flo AF claim 5 , and Formulation T incorporating Dry-Flo TS.8. A method of applying the formulation of any one of to comprising topically administering onto the skin of a dog or cat a dose of such formulation sufficient to result in transdermal absorption of a therapeutically effective dose of mirtazapine from the surface of the skin into the systemic circulation.9. The method of wherein the dosage of mirtazapine administered in a single daily dose is in the range of 0.05 to 2 mg/kg of weight of the dog or cat to be treated.10. The method of or wherein the ointment placed onto the skin is applied in a volume of 0.05 to 5.0 ml per dose.11. The method of wherein the dose administered is between 0.2 and 5 mg per cat claim ...

Подробнее
Номер записи: 46
25-01-2018 дата публикации

DIACEREIN OR RHEIN TOPICAL FORMULATIONS AND USES THEREOF

Номер: US20180021290A1
Автор: Brown, Chen Chih-Kuang, III Carl Oscar, Lee Jing-Yi, Lu Wei-Shu
Принадлежит:

A topical pharmaceutical composition containing diacerein and/or its analogs is provided. Also provided is a method for treating various diseases using this topical pharmaceutical composition. 1. A topical pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of diacerein , rhein , monoacetylrhein , and salts or esters or prodrugs thereof , and one or more pharmaceutically acceptable excipients , wherein the composition is in the form of ointment , and at least about 90% by volume of the compound has a particle size of about 0.5 to about 35 μm.2. The composition of claim 1 , wherein at least about 90% by volume of the compound has a particle size of about 10 to about 30 μm.3. The composition of claim 1 , wherein at least about 90% by volume of the compound has a particle size of about 12 to about 25 μm.4. The composition of claim 1 , wherein the pharmaceutically acceptable excipient comprises an ointment base claim 1 , an ointment base modifier claim 1 , and a surfactant.5. The composition of claim 1 , wherein the compound is present in an amount between about 0.1% to about 10.0% w/w of the total composition.6. The composition of claim 1 , wherein the compound is present in an amount between about 0.1% to 5.0% w/w of the total composition.7. The composition of claim 1 , wherein the compound is present in an amount between about 0.5% to about 2.0% w/w of the total composition.8. The composition of claim 1 , comprising about 0.1% to about 10% w/w of the compound claim 1 , about 15% to about 99% w/w of an ointment base claim 1 , about 0% to about 60% w/w of an ointment base modifier claim 1 , and about 0% to about 10% w/w of a surfactant claim 1 , based on the total weight of the composition.9. The composition of claim 1 , comprising about 1% w/w of the compound claim 1 , about 84.5% w/w of an ointment base claim 1 , about 12% w/w of an ointment base modifier claim 1 , and about 2% w/w of a surfactant ...

Подробнее
Номер записи: 47
24-01-2019 дата публикации

Method for hardfacing a metal article

Номер: US20190022786A1
Автор: Dechao Lin
Принадлежит: General Electric Co

A method for hardfacing a metal article is disclosed including applying a first pass of a metal composition to a surface of the metal article along a first application path, applying a second pass of the metal composition to the surface along a second application path, and applying a third pass of the metal composition to the surface along a third application path between the first application path and the second application path. The first pass and the second pass form a hardfacing perimeter, and the third pass fills in the hardfacing perimeter.

Подробнее
Номер записи: 48
24-01-2019 дата публикации

MONOBLOCK BRAKE CALIPER AND MANUFACTURING METHOD THEREOF

Номер: US20190024733A1
Автор: Lee Young Sik
Принадлежит:

Disclosed is a monoblock brake caliper comprising a caliper body including an arcuate section in an arc shape to partially surround a brake disc, and a side section formed at both sides of the arcuate section and positioned in close proximity to both sides of the brake disc; a brake hydraulic line disposed inside the caliper body and configured to be insert-cast during the casting of the caliper body so as to be formed as a U-shaped pipe; and a metal core disposed on the inner side of the side section of the caliper body so as to be positioned adjoining the brake hydraulic line at a portion where a piston is to be disposed during the casting of the caliper body so that the metal core is removed from the caliper body after the casting of the caliper body to form a cylinder in the caliper body. 1. A monoblock brake caliper comprising:{'b': 10', '11', '12', '11', '11', '12, 'a caliper body () including an arcuate section () formed in an arc shape so as to partially surround a brake disc, and a side section () formed at both sides of the arcuate section () and positioned in close proximity to both sides of the brake disc, the arcuate section () and the side section () being integrally formed with each other by casting;'}{'b': 20', '10', '10, 'a brake hydraulic line () disposed inside the caliper body () and configured to be insert-cast during the casting of the caliper body () so as to be formed as a U-shaped pipe; and'}{'b': 30', '12', '10', '20', '14', '10', '30', '10', '10', '13, 'a metal core () disposed on the inner side of the side section () of the caliper body () so as to be positioned adjoining the brake hydraulic line () at a portion where a piston () is to be disposed during the casting of the caliper body () so that the metal core () is removed from the caliper body () after the casting of the caliper body () to form a cylinder () in the caliper body.'}22013302013. The monoblock brake caliper according to claim 1 , wherein an adjoining portion between the ...

Подробнее
Номер записи: 49
02-02-2017 дата публикации

METHODS FOR ALLEVIATING ACNE AND METHODS FOR TREATING A SEBACEOUS GLAND

Номер: US20170027983A1
Автор: Anderson Richard Rox, Farinelli William A., van Hamel Platerink Gerard
Принадлежит: The General Hospital Corporation

One aspect of the invention provides a method for alleviating acne including: applying a therapeutic substance to an area of skin having follicles, said therapeutic substance comprising a plurality of metal nanoparticles within a carrier; using a device to impart mechanical energy to deliver some of said therapeutic substance into a plurality of follicles; removing the composition remaining on the skin surface while leaving the therapeutic substance in said follicles; and irradiating the skin to which the composition was applied with light energy effective to treat acne. 1. A method for alleviating acne comprising:a) applying a therapeutic substance to an area of skin having follicles, said therapeutic substance comprising a plurality of metal nanoparticles within a carrier;b) using a device to impart mechanical energy to deliver some of said therapeutic substance into a plurality of follicles;c) removing the composition remaining on the skin surface while leaving the therapeutic substance in said follicles; andd) irradiating the skin to which the composition was applied with light energy effective to treat acne.2. The method of claim 1 , wherein said metal nanoparticles comprise gold nanoparticles.3. The method of claim 1 , wherein the use of a device to impart mechanical energy further comprises delivering some of said therapeutic substance into proximity to claim 1 , or within claim 1 , a plurality of sebaceous glands.4. A method for alleviating acne comprising:a) applying a therapeutic substance to an area of skin having follicles, said therapeutic substance comprising gold nanoparticles within a carrier;b) using a device imparting mechanical energy to deliver some of said therapeutic substance into follicles and in close proximity to, or within, a sebaceous gland;c) removing the composition remaining on the skin surface, while leaving the therapeutic substance in proximity to or within the sebaceous gland; andd) irradiating the skin to which the composition was ...

Подробнее
Номер записи: 50
31-01-2019 дата публикации

Delivery of Oligonucleotide-Functionalized Nanoparticles

Номер: US20190030185A1
Автор: Giljohann David A., Mirkin Chad A., Paller Amy S.
Принадлежит:

The present invention relates to compositions and methods for delivering an oligonucleotide-functionalized nanoparticle. 1. A method of dermal delivery of an oligonucleotide-functionalized nanoparticle comprising the step of:administering a therapeutically effective amount of a composition comprising the oligonucleotide-functionalized nanoparticle and a dermal vehicle to the skin of a patient in need thereof.2. The method of wherein the delivery of the oligonucleotide-functionalized nanoparticle is transdermal.3. The method of wherein the delivery of the oligonucleotide-functionalized nanoparticle is topical.4. The method of claim 1 , said dermal vehicle comprising an ointment.5. The method of wherein the ointment is Aquaphor.6. A method of regulating gene expression comprising the step of:administering a therapeutically effective amount of a composition comprising an oligonucleotide-functionalized nanoparticle to skin under conditions wherein the oligonucleotide-functionalized nanoparticle hybridizes to a target and regulates gene expression.7. The method of wherein the target is a polypeptide.8. The method of wherein the target is a polynucleotide.9. The method of wherein the polynucleotide is RNA.10. The method of or wherein the administration of the composition ameliorates a skin disorder.11. The method of wherein the skin disorder is selected from the group consisting of cancer claim 10 , a genetic disorder claim 10 , aging claim 10 , inflammation claim 10 , infection claim 10 , and cosmetic disfigurement.12. The method of wherein the cancer is selected from the group consisting of squamous cell carcinoma claim 11 , basal cell carcinoma claim 11 , breast cancer and melanoma.13. The method of wherein the target is a gene product expressed by a gene selected from the group consisting of Ras claim 12 , IκBα claim 12 , hedgehog claim 12 , B-Raf claim 12 , Akt and cyclin D.14. The method of wherein the genetic disorder is selected from the group consisting of ...

Подробнее
Номер записи: 51
31-01-2019 дата публикации

COMPACTOR TOOTH, BASE THEREFOR AND RELATED METHOD

Номер: US20190032295A1
Автор: McCartney Neil
Принадлежит: Bernard McCartney Limited

A base for forming a tooth for a wheel of a landfill compactor vehicle is disclosed. The tooth comprises said base and a cap of a cast metal material formed on said base. The base comprises a block, a core and a lip. The block is adapted to be mounted on said landfill compactor vehicle wheel. The core, which is disposed on a cap-facing side of the base, is for receiving molten metal material during a casting operation and remains embedded in the cap. The lip is disposed around a periphery of the base and is also for receiving said molten metal material, in cooperation with the core. The lip at least partially surrounds the cap-facing side and the core and helps in reducing or preventing imperfections, such as cracks, which could otherwise form at the interface between the base and the cap following the casting operation. 1. A base for forming a tooth for a wheel of a landfill compactor vehicle , the tooth comprising said base and a cap of cast metal material formed on said base , the base comprising:a block adapted to be mounted on said landfill compactor vehicle wheel;a core for receiving a molten metal material, said core being disposed on a cap-facing side of said base; and,a lip for receiving said molten metal material in cooperation with the core, the lip being disposed around the base at least partially surrounding the cap-facing side and the core.2. The base of claim 1 , wherein the lip is integrally formed with the block.3. The base of claim 1 , wherein at least part of the core is above an upper surface of the lip of the base.4. The base of claim 1 , wherein a recess is formed between the lip and the core.5. The base of any claim 1 , wherein the lip has a cross-sectional area of between 25 mmand 2500 mmalong its length.6. The base of claim 1 , wherein the lip has a generally constant cross-sectional area along its length.7. The base of any claim 1 , wherein the lip has a cross-sectional profile of one of a rectangle claim 1 , square claim 1 , triangle or ...

Подробнее
Номер записи: 52
08-02-2018 дата публикации

IONIC NANOVESICLE SUSPENSION AND BIOCIDE PREPARED THEREFROM

Номер: US20180036236A1
Автор: Selner Marc
Принадлежит:

A stable suspension, containing water, petrolatum, and at least one ionic biocide compound, wherein the suspension contains no added emulsifier, and all ionic biocide compounds present are either all cationic or all anionic, an ointment containing the stable suspension, and a method for producing the stable suspension. 1. A stable suspension , comprising water , petrolatum , and at least one ionic biocide compound , wherein the suspension contains no added emulsifier , and all ionic biocide compounds present are either all cationic or all anionic , wherein the at least one ionic biocide is contained within nanovesicles having a diameter of 100 microns or less.2. The stable suspension of claim 1 , wherein all ionic biocide compounds present are all cationic biocides.3. The stable suspension of claim 1 , wherein all ionic biocide compounds present are all anionic biocides.4. The stable suspension of claim 1 , wherein the at least one ionic biocide compound is selected from the group consisting of polyhexanide (PHMB) claim 1 , polyaminopropyl biguanide (PAPB) claim 1 , benzalkonium chloride claim 1 , stearalkonium chloride claim 1 , sodium hypochlorite and ethylenediaminetetraacetic acid (EDTA).5. The stable suspension of claim 4 , wherein the at least one ionic biocide compound is a combination of PHMB and benzalkonium chloride.6. The stable suspension of claim 1 , wherein the suspension further comprises at least one nonionic biocide compound.7. The stable suspension of claim 1 , wherein the suspension further comprises at least one additional medicament.8. The stable suspension of claim 7 , wherein the at least one additional medicament is a steroid.9. The stable suspension of claim 8 , wherein the steroid is cortisone.10. A biocidal ointment prepared from the stable suspension of .11. A method for preparing the stable suspension of claim 1 , comprising:separately heating the petrolatum and a mixture of the water and the at least one ionic biocide compound, each to ...

Подробнее
Номер записи: 53
18-02-2016 дата публикации

ANTIVIRAL PHARMACEUTICAL FOR TOPICAL ADMINISTRATION

Номер: US20160045431A1
Автор: Squiquera Luis, Sulley Jamie
Принадлежит: Tamir Biotechnology, Inc.

An enzymatically-active ribonuclease is combined with a vehicle that does not unacceptably interfere with such enzymatic activity and applied externally. Advantageously, the ribonuclease is ranpirnase. The vehicle can be a liquid, a gel, an ointment, or a serum, and can also be an approved sexual lubricant. 1. A pharmaceutical comprising a therapeutically effective quantity of an enzymatically-active ribonuclease and a vehicle that does not unacceptably interfere with such enzymatic activity.2. The pharmaceutical of claim 1 , wherein the enzymatically-active ribonuclease is ranpirnase.3. The pharmaceutical of claim 1 , wherein the vehicle is an aqueous vehicle.4. The pharmaceutical of claim 3 , wherein the vehicle is a gel claim 3 , a serum claim 3 , or a lotion.5. The pharmaceutical of claim 3 , wherein the vehicle is an approved sexual lubricant.6. The pharmaceutical of claim 1 , wherein the vehicle is compatible with latex condoms.7. The pharmaceutical of claim 2 , wherein the pharmaceutical contains between 1 and 3 mg of ranpirnase per ml of vehicle.8. The pharmaceutical of claim 2 , wherein the concentration of ranpirnase in the pharmaceutical is chosen to deliver between 1 and 3 mg of ranpirnase to the patient each week that the pharmaceutical is administered to the patient in accordance with the dosage regimen used. The invention relates to antiviral pharmaceuticals, and more particularly relates to antiviral pharmaceuticals for topical administration. In its most immediate sense, the invention relates to pharmaceuticals for treating patients with anogenital warts.Ranpirnase is a protein with ribonuclease activity, it has a molecular weight of approximately 12,000 Daltons, and it has an amino acid sequence disclosed and claimed in U.S. Pat. No. 5,559,212. It can be isolated from embryos and eggs of the frog or produced as a recombinant protein (see e.g. Patent No. U.S. Pat. No. 6,175,003 B1). Commonly-owned patent number U.S. Pat. No. 8,663,964 B2 teaches ...

Подробнее
Номер записи: 54
15-02-2018 дата публикации

TOPICAL HALOBACTERIA EXTRACT COMPOSITION FOR TREATING RADIATION SKIN TISSUE DAMAGE

Номер: US20180042971A1
Автор: KUCHINA Nona
Принадлежит: DR. NONA INTERNATIONAL LTD.

The present invention provides a composition for treating skin damage, comprising Halobacteria extracts and extracts. The aforementioned extracts further comprising strong antioxidants with high redox potential when dissolved in oil and in water. The strong antioxidants inhibiting in a known oxidative mechanisms which are further correlated with skin damage, wherein the Halobacteria extract is Archaebacteria DN-1 having a wide range impact on rehabilitation of the skin tissue after radiation, and wherein said Halobacteria extracts and extracts combination promotes rehabilitation of the skin tissue after radiation, and provides a synergistic effect on a mammalian skin. Furthermore, the composition is preferably adapted for topical delivery. 1. A topical composition for treating skin damage comprisinga. Halobacteria extracts; and{'i': 'Dunaliella', 'b. extracts for reducing the amount of free radicals in skin damage;'}wherein said Halobacteria extracts comprise strong antioxidants with high redox potential; said strong antioxidants inhibiting known oxidative mechanisms correlated with skin damage said topical composition has synergistic anti-inflammatory effect, defined by attenuation of at least of Il-1β or TNF-α induction on said inflamed skin as compared to an untreated control skin.2. The composition according to claim 1 , wherein said Halobacteria extract is Halobacteria homogenate Archaebacteria DN1 claim 1 , and said Archaebacteria DN-1 has an anti-oxidant activity substantially correlated with a body serum total antioxidant capacity (TAC) of at least 167.1 μMol Trolox Equivalent/100 g; said anti-oxidant activity measured at the treatment site by at least one assay selected from the group consisting of:i. Assay 1—oxygen radical absorbent capacity (ORAC);ii. Assay 2—of ferric reducing ability of plasma (FRAP);iii. Assay 3—of 2,2-diphenyl-1-picrylhydrazyl (DPPH);iv. Assay 4—of 3-ethyl-benzothiazoline-6-sulfonic acid (ABTS);v. Assay 5—of Trolox Equivalent ...

Подробнее
Номер записи: 55
01-05-2014 дата публикации

Methods of Treating Psoriasis Using Allantoin

Номер: US20140121255A1
Автор: FARBER Elliott
Принадлежит: Scioderm, Inc.

Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof. Symptoms treated may include pain, inflammation, redness, itching, scarring, skin thickening, milia, or a combination thereof. 127-. (canceled)28. A method for treating or reducing reoccurrence of psoriasis in a patient in need thereof comprising contacting the patient's skin with an effective amount of a composition comprising allantoin in an amount from about 3.0% to about 15% by weight and a pharmaceutically acceptable excipient.29. The method of claim 28 , wherein the composition is administered to the subject daily.30. The method of claim 28 , wherein the allantoin is in an amount of about 3.0% to about 9.0%.31. The method of claim 28 , wherein the composition results in penetration of the allantoin across the skin membrane of the patient in a dose dependent manner.32. The method of claim 28 , wherein the composition results in penetration of the allantoin across the skin membrane of the patient without an increase in systemic blood levels of allantoin in the patient.33. The method of claim 28 , wherein the ...

Подробнее
Номер записи: 56
19-02-2015 дата публикации

Mucins as Antiviral Compounds

Номер: US20150051139A1
Автор: Lieleg Oliver, Ribbeck Katharina
Принадлежит: Massachusetts Institute of Technology

The invention provides methods, and compositions for performing the methods, that reduce the diffusion or overall mobility of a virus on a surface, such as a biological surface using a purified mucin. The methods can reduce the infectivity of a virus for a cell on the surface. In particular embodiments, the mucin can be a non-human mucin, such as a procine gastric mucin. 1. A method of inhibiting infection of one or more cells by a virus comprising contacting the one or more cells with a composition comprising biocompatible , purified , non-human gastric mucin , wherein the virus is not a Norovirus.2. The method of wherein the non-human gastric mucin is porcine gastric mucin.3. The method of claim 2 , wherein the porcine gastric mucin is MUC-5AC.47-. (canceled)8. The method of claim 1 , wherein the gastric mucin concentration is about 0.20% (w/v) claim 1 , 0.25% (w/v) claim 1 , 0.30% (w/v) claim 1 , 0.35% (w/v) claim 1 , 0.40% (w/v) claim 1 , 0.45% (w/v) claim 1 , 0.50% (w/v) claim 1 , 0.55% (w/v) claim 1 , 0.6% (w/v) claim 1 , 0.65% (w/v) claim 1 , 0.7% (w/v) claim 1 , 0.75% (w/v) claim 1 , 0.8% (w/v) claim 1 , 0.85% (w/v) claim 1 , 0.9% (w/v) claim 1 , 0.95% (w/v) claim 1 , 1% (w/v) claim 1 , 1.5% (w/v) claim 1 , 2.0% (w/v) claim 1 , 2.5% (w/v) when hydrated.9. The method of claim 8 , wherein the mucin concentration is between about 0.125 to about 2.0% (W/V).10. The method of claim 9 , wherein the mucin concentration is between about 0.2 to about 1.2% (W/V).1113-. (canceled)14. The method of claim 1 , wherein the composition has a pH of about 2 to about 4.15. The method of claim 1 , wherein the composition has a salt concentration with an ionic strength equivalent to a 1:1 electrolyte of about 20 nM claim 1 , 40 mM claim 1 , 60 mM claim 1 , 80 mM claim 1 , 100 mM claim 1 , 120 mM claim 1 , 140 mM claim 1 , 160 mM claim 1 , 180 mM claim 1 , 200 mM claim 1 , 220 mM claim 1 , 240 mM claim 1 , 260 mM claim 1 , 280 mM claim 1 , 300 mM claim 1 , 320 mM claim 1 , 340 mM ...

Подробнее
Номер записи: 57
23-02-2017 дата публикации

METHODS FOR TREATING BURNS USING ALLANTOIN

Номер: US20170049749A1
Автор: Ryan Robert
Принадлежит: Scioderm.Inc.

Embodiments of the present invention relate generally to compositions comprising an effective amount of allantoin that can be used to treat skin burns. The compositions are preferably formulated as topical formulations, e.g., oil-in-water emulsions. Embodiments herein provide formulations and methods for treating skin burns using allantoin in an amount from about 2.5% to about 15.0% by weight. 1. A method of treating a skin burn on a patient comprising administering to the burn a composition comprising allantoin in an amount from about 2.5% to about 15% by weight and a pharmaceutically acceptable excipient.2. The method of claim 1 , wherein the skin burn is caused by heat claim 1 , electricity claim 1 , chemicals claim 1 , friction claim 1 , radiation claim 1 , or combinations thereof.3. The method of claim 2 , wherein the skin burn is caused by heat.4. The method of any one of - claim 2 , wherein the skin burn is a first degree burn or a second degree burn.5. The method of any one of - claim 2 , wherein the skin burn is a third degree burn or a third degree burn treated with a skin graft.6. The method of any one of - claim 2 , wherein the composition is an oil-in-water emulsion further comprising an emollient and an emulsifier.7. The method of claim 6 , wherein the emollient is selected from the group consisting of lanolin oil claim 6 , cod liver oil claim 6 , mineral oil claim 6 , an alcohol claim 6 , and any combination thereof.8. The method of claim 6 , wherein the emulsifier is selected from the group consisting of sodium laurate sulfate claim 6 , a white wax claim 6 , and a combination thereof.9. The method of any one of - claim 6 , wherein the composition further comprises a pH modifier claim 6 , a solubilizing agent claim 6 , an antioxidant claim 6 , a preservative claim 6 , a chelating agent claim 6 , a viscosity agent or any combination thereof.10. The method of claim 9 , wherein the pH modifier is citric acid; the solubilizing agent is propylene glycol; ...

Подробнее
Номер записи: 58
01-03-2018 дата публикации

TOPICAL ARTHRITIS TREATMENT DEVICE

Номер: US20180055878A1
Автор: Hendricks Jeffrey P., Hendricks Teresa
Принадлежит:

The present disclosure relates to a method of forming a topical treatment device for arthritis. The method can include determining an arthritis treatment surface area of a user, forming a flexible metal substrate conforming to the arthritis treatment surface area, and forming a gold composition on the flexible metal substrate. 1. A topical treatment device for arthritis comprising:a flexible metal substrate conformed to a user treatment surface area; andat least one gold-containing composition formed on the metal substrate.2. The topical treatment device of wherein the flexible metal substrate is chainmail.3. The topical treatment device of wherein the chainmail is steel.4. The topical treatment device of comprising a first gold-containing composition formed on the metal substrate and a second gold-containing composition formed on the first gold-containing composition.5. The topical treatment device of wherein the second gold-containing composition is 24 karat gold.6. The topical treatment device of wherein at least one of the first or second gold-containing compositions comprises at least 14 karat gold.7. The topical treatment device of wherein the gold composition of the first gold-containing composition is different from the gold composition of the second gold-containing composition.8. The topical treatment device of wherein at least one of the first or second gold-containing composition is formed by plating.9. The topical treatment device of wherein at least one of the first or second gold-containing composition is formed by a barrel plating process.10. The topical treatment device of wherein the first gold-containing composition has a hardness of 200 HK.11. The topical treatment device of wherein the second gold-containing composition has a hardness between 200 and 400 HK.12. The topical treatment device of wherein the flexible metal substrate is tailored to fit the user treatment surface area.13. The topical treatment device of wherein the flexible metal ...

Подробнее
Номер записи: 59
04-03-2021 дата публикации

THERMOSENSITIVE HYDROGEL COLLAGENASE FORMULATIONS

Номер: US20210060143A1
Автор: Wegman Thomas L., Yu Bo
Принадлежит: BioSpecifics Technologies Corp.

It is an object of the present disclosure to provide a formulation for injectable and topical collagenase, which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated. It is a further object of the disclosure to provide a slow release formulation for collagenase, which is compatible with the active ingredient and does not adversely affect its activity. Still a further object of the disclosure is to provide an injectable formulation for collagenase which can be effectively administered to a patient with a small size needle without exhibiting pre-gelation, which would interfere with the ability to deliver the required dose for treatment. Still a further object of the disclosure is to provide a water-based topical formulation for collagenase which will be more compatible with other topically used medications to achieve better results. 1. A composition for treating a collagen-mediated disease , comprising collagenase and a carrier that provides sustained release of an amount of said collagenase sufficient to treat said collagen-mediated disease.2. The composition of claim 1 , wherein said carrier comprises gel-forming polymers.3. The composition of claim 2 , wherein said polymer is a triblock polymer or a copolymer based on N-siopropylacrylamide (NIPAAm)4. The composition of claim 3 , wherein said triblock polymers comprise poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG).5. The composition of claim 4 , wherein said polymers comprise a copolymer formed from PLGA and polyethylene glycol (PEG).6. The composition of claim 5 , wherein the PLGA and PEG copolymers are formed in repetitions of PLGA-PEG-PLGA or PEG-PLGA-PEG.7. The composition of claim 1 , wherein said composition is injectable claim 1 , insertable or applied topically.8. The composition of claim 1 , which can be administered through a syringe fitted with a 28G1/2 needle without pre-gelation in the needle on injection.9. The composition ...

Подробнее
Номер записи: 60
20-02-2020 дата публикации

DEMONSTRABLE EFFICACY ACROSS OR WITHIN PATIENT POPULATIONS

Номер: US20200054722A1
Автор: Edelson Jonathan
Принадлежит:

The present invention provides methods for improving observed or determined efficacy by administration of agents to more severely diseased subjects, as contrasted with less severely diseased subjects. The present disclosure specifically demonstrates that, with respect to treatment of certain skin conditions, and particularly conditions associated with dysregulated and/or diseased skin cells, administration to more severely diseased subjects improves observed or determined efficacy. 1. A method comprising steps of:a) determining the severity of hyperhidrosis in individual subjects by stratifying the subjects into two or more categories based on hyperhidrosis severity, so that a first category comprises subjects having severe hyperhidrosis relative to at least a second category that comprises subjects having hyperhidrosis who are not severely diseased; andb) administering the treatment to subjects in the first category and not to subjects not in the first category, wherein the treatment comprises transdermal administration of botulinum toxin A;wherein the treatment has been demonstrated to achieve a reduction of 25% or more in perspiration when administered to the subjects in the first category; and not to achieve said reduction when administered to subjects in the second category.2. The method of claim 1 , wherein the hyperhidrosis in the subjects having severe hyperhidrosis is characterized by elevated frequency or severity of hyperhidrosis symptoms claim 1 , and/or earlier onset of such symptoms claim 1 , relative to the hyperhidrosis in the subjects who are not severely diseased.318.-. (canceled)19. The method of claim 1 , wherein the hyperhidrosis is categorized as palmar claim 1 , axillary claim 1 , plantar claim 1 , facial claim 1 , cranial claim 1 , or general hyperhidrosis.20. The method of claim 1 , wherein the subjects having severe hyperhidrosis have 200 mg gravimetric sweat production (GSP) or more; and wherein the subjects having hyperhidrosis who are ...

Подробнее
Номер записи: 61
11-03-2021 дата публикации

Hardbanding Method and Apparatus

Номер: US20210071484A1
Автор: Miller Robert F.
Принадлежит:

Various methods of hardbanding an apparatus are described. In one aspect of the invention an improved method of re-applying a hardbanding alloy to worn tool joints of a previously hardbanded drill pipe results in preservation of the metallurgical properties of the drill pipe and preservation of the internal polymer coating that lines the drill pipe. A method for applying hardbanding includes arc welding a consumable metal welding wire to a tool joint having a surface temperature that ranges from about 50° F. to about 170° F. and the arc welding power supply utilizes DC current. The method herein produces a hardbanded tool joint comprising a heat affected zone (HAZ) of a based metal having a Rockwell hardness of 40 Rc or less. 116-. (canceled)17. A hardbanded tool joint comprising:an internal lining comprising polymer;a base metal zone comprising a base metal;a base metal heat affected zone (HAZ) having a Rockwell hardness of about 40 Rockwell Hardness (Rc) or less;a previously applied hardband weld zone comprising a hardband metal;a stringer bead weld zone comprising a stringer weld metal; andwherein the base metal heat affected zone (HAZ) is between the base metal and the previously applied hardband weld zone.18. The hardband tool joint of claim 17 , comprising:a stringer bead heat affected zone (HAZ) disposed between the previously applied hardband weld zone and the stringer bead weld zone.19. The hardbanded tool joint of claim 17 , wherein the stringer bead weld zone is external to the base metal heat affected zone (HAZ) throughout the tool joint.20. The hardbanded tool joint of claim 17 , wherein the stringer bead weld zone comprises from about 6 to about 12 weld beads over a length of about three inches of the tool joint.21. The hardbanded tool joint of claim 17 , wherein the stringer bead weld zone comprises from about 7 to about 11 weld beads over a length of about three inches of the tool joint.22. The hardbanded tool joint of claim 17 , wherein the hardband ...

Подробнее
Номер записи: 62
17-03-2016 дата публикации

AGRICULTURAL BLADES AND MACHINE PARTS WITH AMORPHOUS METAL LASER CLADDING

Номер: US20160073582A1
Автор: Baez Heather, Johnson Keith A., Placek Casey, Stoffel Neal J.
Принадлежит: Kondex Corporation

A laser cladded agricultural blade is provided. The blade includes a blade body. The blade body is of a first hardness. The blade body is additionally provided with a cladding material of a second hardness, wherein the cladding material comprises an amorphous metal. The cladding material is applied by a laser cladding process. 1. A machine part for agricultural , turf , mining or construction equipment for processing material , comprising:a body comprising a base material;a clad material deposited on the base material and forming at least one edge along the body, the clad material comprising a second hardness greater than the first hardness, wherein the clad material is at least partially amorphous.2. The machine part of claim 1 , wherein the machine part includes a material thickness defined between two sides claim 1 , the two sides defining width and length spans that are each at least 5 times or more than the material thickness claim 1 , wherein a material thickness edge forms a periphery of the body and extends between the two sides claim 1 , wherein the material thickness edge extends transversely between the two sides.3. The machine part of claim 2 , wherein the clad material is deposited along the one of the two sides.4. The machine part of claim 2 , wherein the clad material is deposited along the material thickness edge.5. The machine part of claim 3 , wherein the body comprises a sheet steel formed component part having a substantially uniform material thickness.6. The machine part of claim 1 , wherein the clad material is applied to less than 15 percent of surface area of the machine part.7. The machine part of claim 1 , wherein the clad material comprises less than 5 percent of the machine part by weight.8. The machine part of claim 2 , wherein the material thickness edge defines an angled cutting edge.9. The machine part of claim 8 , wherein the angled cutting edge defines an acute angle between 30 and 60 degrees.10. The machine part of claim 1 , ...

Подробнее
Номер записи: 63
15-03-2018 дата публикации

PREVENTING OR TREATING VIRAL INFECTION BY INHIBITION OF THE HISTONE METHYLTRANSFERASE EZH1 OR EZH2

Номер: US20180071284A1
Автор: Arbuckle Jesse H., Kristie Thomas M.
Принадлежит: The United States of America, as represented by the Secretary, Department of Health and Human Serv

Disclosed are methods of preventing or treating a viral infection of a host, the method comprising administering to the host an effective amount of an inhibitor of the histone methyltransferase activity of EZH1 or EZH2. In one embodiment, the method comprises administering to the host an effective amount of a compound of Formula (I): 1. A method of treating viral infection , the method comprising administering to a subject in need thereof an effective amount of an inhibitor of the EZH1 and/or EZH2 histone methyltransferase activities , wherein the viral infection is due to a herpesvirus or adenovirus or flavivirus.6. The method of claim 1 , wherein the viral infection involves reactivation of a virus after latency in the subject.7. The method of claim 1 , wherein the viral infection is due to a herpesvirus or adenovirus claim 1 , wherein the herpesvirus is herpes simplex type 1 and wherein the adenovirus is adenovirus 5.8. The method of claim 1 , wherein the viral infection is acute.9. The method of claim 1 , wherein the composition is a topical medicament.14. The method of claim 2 , wherein the viral infection involves reactivation of the virus after latency in the subject.15. The method of claim 2 , wherein the viral infection is due to a herpesvirus or adenovirus or flavivirus.16. The method of claim 2 , wherein the viral infection is acute.17. The method of claim 2 , wherein the composition is a topical medicament. This application is a continuation-in-part of International Patent Application No. PCT/US2016/030089, filed Apr. 29, 2016, which claims the benefit of U.S. Provisional Patent Application No. 62/155,704, filed May 1, 2015, each of which is incorporated herein by reference in its entirety.This invention was made with Government support under project numbers ZIA AI000712 LVD and ZIA AI000711 LVD by the National Institutes of Health, National Institute of Allergy and Infectious Diseases. The Government has certain rights in the invention.Herpes viral ...

Подробнее
Номер записи: 64
19-03-2015 дата публикации

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS

Номер: US20150080313A1
Автор: Selmaj Krzysztof, Szczepanik Marian
Принадлежит:

The subject of the present invention is pharmaceutical composition containing active ingredients in the form of a peptide of the myelin basic protein, a peptide from the myelin protein and oligodendrocytes as well as a peptide of the proteolipid protein as well as the use of the composition in the manufacturing of a drug for topical administration in the treatment of the disease multiple sclerosis. The composition may be administered topically. 1. A pharmaceutical composition containing a peptide selected from a group encompassing: a peptide derived from the myelin basic protein , a peptide derived from myelin protein and oligodendrocytes , as well as a peptide derived from proteolipid protein for use in the treatment of multiple sclerosis , possibly in a form designed for topical administration.2. The pharmaceutical composition according to claim 1 , characterised in that it contains an MBP peptide with the Seq. ID No. 1 claim 1 , a MOG peptide with the Seq. ID No. 2 as well as a PLP peptide with the Seq. ID No. 1.3. The pharmaceutical composition according to claim 1 , characterised in that it is useful for lowering the annualized relapse rate (ARR) in patients.4. The pharmaceutical composition according to claim 1 , characterised in that it is useful for lowering the rate of development of neurological impairment.5. The pharmaceutical composition according to claim 1 , characterised in that it is useful for lowering the number of new changes observed in patients as measured by magnetic resonance.6. The pharmaceutical composition according to claim 1 , characterised in that it is useful for lowering the volume of new changes observed in patients as measured by magnetic resonance.7. The pharmaceutical composition according to claim 1 , characterised in that it is useful for decreasing the rate of progression of the disease over the year following the end of treatment.8. The pharmaceutical composition according to claim 7 , characterised in that the decrease in the ...

Подробнее
Номер записи: 65
23-03-2017 дата публикации

Method for Adjusting the Release of Active Agent in a Transdermal Delivery system

Номер: US20170079932A1
Автор: EMGENBROICH Marco, Leonhard Johannes Josef, Wolff Hans-Michael
Принадлежит:

Use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, wherein the inner phase comprises the additive and an active agent dissolved therein, wherein the additive has a higher affinity to water than to the active agent, for the control of the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, wherein the maintenance of the permeation rate is proportional to the amount of active agent in the biphasic layer. 2. The use in accordance with claim 1 , wherein said additive forms a solid solution with the active agent.3. The use in accordance with any one of or claim 1 , wherein said active agent has a log P value of more than 3 to about 6.4. The use in accordance with any one of to claim 1 , wherein said active agent has a water solubility of about 1 mg/L to less than 100 mg/L.5. The use in accordance with any one of to claim 1 , wherein the active agent is present in a concentration of about 1% to about 30% of the biphasic layer.6. The use in accordance with any one of to claim 1 , wherein said active agent is selected from the group consisting of rotigotine claim 1 , fentanyl claim 1 , oxybutynine claim 1 , and fesoterodine.7. The use in accordance with any one of to claim 1 , wherein the active agent is present in an amount of 0.1 mg/cmto 10.0 mg/cmof the biphasic layer.8. The use in accordance with any one of to claim 1 , wherein said additive is a hygroscopic composition.9. The use in accordance with any one of to claim 1 , wherein said additive is a hygroscopic polymer or a mixture of hygroscopic polymers which is/are able to take up water from about 1% up to about 60%.10. The use in accordance with any one of to claim 1 , wherein said additive is a hygroscopic polymer or a mixture of hygroscopic polymers selected from the group consisting of:polyvinylpyrrolidones, ...

Подробнее
Номер записи: 66
26-03-2015 дата публикации

TREATMENT METHOD FOR STEROID RESPONSIVE DERMATOSES

Номер: US20150087683A1
Автор: Agarwal Pankaj, KUMAR Vinod, Xie Qing
Принадлежит:

Invented is a method of treating steroid responsive dermatoses in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a compound selected from the group consisting of: N-{(1S)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof, and the compound N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide or a pharmaceutically acceptable salt thereof, to such mammal. 1. A method of treating steroid responsive dermatoses in a mammal in need thereof which comprises administering a therapeutically effective amount of a compound selected from: N-{(1S)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof; and N-{(1S)-2-amino-1-[(3 ,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide or a pharmaceutically acceptable salt thereof; to such mammal.2. The method of wherein the mammal is a human.3. The method of wherein the administered compound is N-{(1S)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof.4. The method of wherein the administered compound is N-{(1S)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride.5. The method of wherein the administered compound is N-{(1S)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide.6. The method wherein the administered compound is N-{(1S)-2-amino-1-[(3 claim 2 ,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide or a pharmaceutically acceptable salt thereof.7. The method of ...

Подробнее
Номер записи: 67
31-03-2016 дата публикации

Method for Topically Treating Actinic Keratosis on the Trunk (except chest) or Extremities with Ingenol 3-(3,5-diethylisoxazole-4-carboxylate)

Номер: US20160089362A1
Автор: Knudsen Kim Mark, Selmer Johan
Принадлежит:

The invention relates to the treatment of actinic keratosis on the trunk (except chest) or Extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate). 1. A method of treating a subject diagnosed with actinic keratosis on the trunk (except chest) or extremities , said method comprising applying an effective amount of ingenol 3-(3 ,5-diethylisoxazole-4-carboxylate) to a treatment area on the trunk (except chest) or extremities for two days.2. The method of claim 1 , wherein the method provides a reduction in the number of actinic keratosis in the treatment area.3. The method of claim 1 , wherein the two day treatment is two consecutive days.4. The method of claim 1 , wherein the treatment area is up to about 250 cm.5. The method of any of the claim 1 , wherein the effective amount of the ingenol 3-(3 claim 1 ,5-diethylisoxazole-4-carboxylate) is applied from a dosage strength formulation of ingenol 3-(3 claim 1 ,5-diethylisoxazole-4-carboxylate) of between about 0.01% and about 0.1%6. The method of any of the claim 1 , wherein the dosage strength formulation of ingenol 3-(3 claim 1 ,5-diethylisoxazole-4-carboxylate) is about 0.018% claim 1 , about 0.025% claim 1 , about 0.037% claim 1 , about 0.05% claim 1 , about 0.075% or about 0.1%7. The method of claim 1 , wherein the amount of the ingenol 3-(3 claim 1 ,5-diethylisoxazole-4-carboxylate) applied is between about 0.162 mg ingenol 3-(3 claim 1 ,5-diethylisoxazole-4-carboxylate)/per day/about 250 cm2 treatment area and about 0.9 mg ingenol 3-(3 claim 1 ,5-diethylisoxazole-4-carboxylate)/per day/about 250 cm2 treatment area.8. The method of any of the claim 1 , wherein the ingenol 3-(3 claim 1 ,5-diethylisoxazole-4-carboxylate) is formulated in a gel.9. The method of claim 1 , wherein the ingenol 3-(3 claim 1 ,5-diethylisoxazole-4-carboxylate) is topically applied in a concentration of from about 0.018% to about 0.1%.10. The method of claim 4 , wherein the ingenol 3-(3 claim 4 ,5-diethylisoxazole-4-carboxylate) is ...

Подробнее
Номер записи: 68
02-04-2015 дата публикации

SUSTAINED RELEASE CARRIER FOR DRUGS

Номер: US20150094262A1
Автор: Inoue Hajime, Kobayashi Kazutoshi, Sumi Naosuke, Suto Kunihiro, Tamada Yasushi
Принадлежит:

The present invention can provide a controlled drug release carrier formed by using a silk fibroin porous material, which has high drug controlled release rate, controllability of the drug controlled release speed, high strength, easy handleability, skin care properties from high biocompatibility, high water retentivity, and capability of efficiently retaining a drug. 1. A controlled drug release carrier formed by using a silk fibroin porous material.2. The controlled drug release carrier according to claim 1 , wherein the silk fibroin porous material is treated by a water-soluble high polymer.3. The controlled drug release carrier according to claim 2 , wherein the water-soluble high polymer is material containing at least one kind selected from a polysaccharide and a polyamino acid.4. The controlled drug release carrier according to claim 3 , wherein the polysaccharide contains at least one kind selected from heparin and chondroitin sulfate.5. The controlled drug release carrier according to claim 1 , wherein the drug to be carried contains a growth factor.6. The controlled drug release carrier according to claim 5 , wherein the growth factor is at least one kind selected from a fibroblast growth factor (FGF) claim 5 , a platelet derived growth factor (PDGF) claim 5 , and an epidermal growth factor (EGF).7. The controlled drug release carrier according to claim 1 , wherein the tensile strength of the porous material is 0.1 to 400 kPa. The present invention relates to a controlled drug release carrier.Conventionally, oral administration is known as a method of administering a drug to a patient. However, oral administration has disadvantages that digestive trouble is caused as a side effect, that drug first passing through the liver cannot be prevented from being metabolized because the liver cannot be bypassed, and that the administration of a drug with a narrow region between the therapeutic concentration and the toxic concentration is hardly controlled.As a means ...

Подробнее
Номер записи: 69
02-04-2015 дата публикации

COMPOUNDS FOR TREATING INFLAMMATION AND PAIN

Номер: US20150094366A1
Автор: BRESSE David M., JONES Gerald S., St. Laurent Joseph P.
Принадлежит:

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ω-(methylthio)alkylnitriles such as 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. 1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-(methylthio)propionitrile , or a pharmaceutically acceptable salt thereof.2. The pharmaceutical composition according to claim 1 , wherein the compound has at least 90% (w/w) purity claim 1 , and the composition is in a topical form of gels claim 1 , creams claim 1 , lotions claim 1 , ointments claim 1 , or patches.3. The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable carrier is an emollient selected from the group consisting of: lauryl lactate claim 2 , diethylene glycol monoethyl ether claim 2 , caprylic/capric triglyceride claim 2 , octisalate claim 2 , silicone fluid claim 2 , squalene claim 2 , and sunflower oil.4. The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable carrier is a permeation enhancer selected from the group consisting of lactate esters and diethylene glycol monoethyl ether.5. The pharmaceutical composition according to claim 4 , further comprising acrylates/C10-30 alkyl and tris(2-hydroxyethyl)amine.6. The pharmaceutical composition according to claim 1 , wherein the compound has at least 90% (w/w) purity claim 1 , and the composition is in an oral form of tablets or capsules.7. A method of treating inflammation or pain claim 1 , comprising the steps of:identifying a subject suffering from inflammation or pain, and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering to the subject the ...

Подробнее
Номер записи: 70
05-05-2022 дата публикации

TOPICAL COMPOSITION

Номер: US20220133677A1
Автор: ALAMA Tammam, KAWAGUCHI Yoshiaki
Принадлежит:

Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters.

Подробнее
Номер записи: 71
05-04-2018 дата публикации

SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS

Номер: US20180092915A1
Автор: Boucher Richard C., JOHNSON Michael Ross, THELIN William Robert
Принадлежит: PARION SCIENCES, INC.

Provided are methods of treating a variety of disorders of the skin with inhibitors of the epithelial sodium channel (ENaC). The inhibitors are represented by formula (I)-(IV): 2. The method of claim 1 , wherein the disorder of the skin is psoriasis.3. The method of claim 1 , wherein the disorder of the skin is an inflammatory disease of the skin.4. The method of claim 1 , wherein the disorder of the skin is a wound.5. The method of claim 1 , wherein the disorder of the skin is a lesion or ulcer of the skin.6. The method of claim 1 , wherein the disorder of the skin is eczema.7. The method of claim 1 , wherein the disorder of the skin is lupus.8. The method of claim 1 , wherein the disorder of the skin is rosacea.9. The method of claim 1 , wherein the disorder of the skin is a skin rash.10. The method of claim 1 , wherein the disorder of the skin is a cold sore claim 1 , shingles or acne.11. The method of claim 1 , wherein the compound represented by formula (I)-(IV) is administered topically.12. The method of claim 1 , wherein the compound represented by formula (I)-(IV) is a pharmaceutically acceptable salt.14. The method of claim 13 , wherein the compound represented by formula (I)-(IV) is administered topically.15. The method of claim 13 , wherein the compound represented by formula (I)-(IV) is a pharmaceutically acceptable salt. This application is a continuation application of U.S. application Ser. No. 15/047,274 filed Feb. 18, 2016, allowed, and claims benefit to U.S. Provisional Application Ser. No. 62/117,724, filed on Feb. 18, 2015, and incorporated herein by reference.The present invention is directed to the use of inhibitors of the epithelial sodium channel (ENaC) for treating a variety of conditions affecting the skin.Skin is the physical barrier separating an organism and its environment, which prevents water loss and protects from chemical, mechanical, and microbial attacks. To perform these functions, the epidermis, as the outer layer of the skin, ...

Подробнее
Номер записи: 72
05-04-2018 дата публикации

MANUFACTURING MACHINE

Номер: US20180093325A1
Автор: Fujishima Makoto, Mezawa Yuhei, MORI Masahiko, SAKAI Shigetsugu, TAKASHIMA Shigeyuki
Принадлежит: DMG MORI CO., LTD.

A manufacturing machine is capable of additive manufacturing. The manufacturing machine includes: a connecting part configured to be connectable to a machine tool capable of subtractive manufacturing; and an additive manufacturing head configured to be positioned in a machining area of the machine tool and discharge a material, when the connecting part is connected to the machine tool. The manufacturing machine for additive manufacturing that can be installed at a low cost is thus provided. 1. A manufacturing machine capable of additive manufacturing , the manufacturing machine comprising:a connecting part configured to be connectable to a machine tool capable of subtractive manufacturing; andan additive manufacturing head configured to be positioned in a machining area of the machine tool and discharge a material, when the connecting part is connected to the machine tool.2. The manufacturing machine according to claim 1 , whereinthe additive manufacturing head enters the machining area through an opening of the machine tool formed by opening a door of the machine tool.3. The manufacturing machine according to claim 1 , further comprising an electrical connector configured to be connected to the machine tool for transmitting claim 1 , from the machine tool claim 1 , a control signal for the additive manufacturing head claim 1 , when the connecting part is connected to the machine tool.4. The manufacturing machine according to claim 1 , further comprising a head drive mechanism configured to move the additive manufacturing head three-dimensionally.5. The manufacturing machine according to claim 1 , further comprising a height adjustment mechanism configured to change a height of the connecting part.6. The manufacturing machine according to claim 1 , whereinthe additive manufacturing head is configured to perform additive manufacturing by discharging material powder and emitting a laser beam to a workpiece, andthe manufacturing machine further comprises:a dolly on ...

Подробнее
Номер записи: 73
06-04-2017 дата публикации

3D FORMED LDS LINER AND METHOD OF MANUFACTURING LINER

Номер: US20170095889A1
Автор: BISHOP Bruce, KIM Jung Hoon, Park June Gun
Принадлежит:

A method of manufacturing a 3D LDS liner includes providing an LDS sheet, forming 3D contoured liners in the LDS sheet, laser structuring circuit patterns on the 3D contoured liners to provide a laser structured circuit pattern, selectively plating the laser structured circuit patterns to form circuits on the 3D contoured liners, and removing the 3D contoured liners from the LDS sheet. A formed LDS liner includes a thin LDS film having a 3D contoured surface vacuum formed from an LDS sheet. The LDS film includes an inner surface and an outer surface. A laser structured circuit pattern is etched into the LDS film, and a conductive layer is selectively plated on the laser structured circuit pattern forming a circuit on the LDS film. The circuit may have a non-planar region. 1. A method of manufacturing a 3D LDS liner , the method comprising:providing an LDS sheet;forming 3D contoured liners in the LDS sheet;laser structuring circuit patterns on the 3D contoured liners to provide laser structured circuit patterns;selectively plating the laser structured circuit patterns to form circuits on the 3D contoured liners; andremoving the 3D contoured liners from the LDS sheet.2. The method of claim 1 , further comprising placing the 3D contoured liners in corresponding electronic devices such that the liners closely follow 3D contoured surfaces of the electronic devices.3. The method of claim 1 , wherein said providing an LDS sheet comprises providing an LDS sheet having a thickness less than 0.3 mm.4. The method of claim 1 , wherein said forming 3D contoured liners comprises forming the planar LDS sheet into non-planar liners.5. The method of claim 1 , wherein said forming the 3D contoured liners comprises vacuum forming the liners.6. The method of claim 1 , wherein said laser structuring circuit patterns comprises laser structuring circuit patterns on both an inner surface of the liner and an outer surface of the liner.7. The method of claim 6 , wherein said selectively ...

Подробнее
Номер записи: 74
26-06-2014 дата публикации

Low Sulfur Nickel Base Substrate Alloy and Overlay Coating System

Номер: US20140178245A1
Автор: Cetel Alan D., Shah Dilip M.
Принадлежит: UNITED TECHNOLOGIES CORPORATION

A coated article having an improved coating oxidation life includes a superalloy substrate material having a composition which includes sulfur, herein the sulfur is present in an amount less than 1 ppm; and an overlay coating formed over a surface of the substrate material. 112-. (canceled)13. A process for forming a coated article having an improved coating oxidation life comprising the steps of:casting a superalloy substrate material having a composition which includes sulfur, wherein said sulfur is present in an amount less than 1 ppm; andforming an overlay coating over a surface of said substrate material.14. A process according to claim 13 , wherein said casting step comprises providing a master heat containing active elements in such a way that [wt. ppm of Mg]+[(24/40)×(wt. ppm of Ca)]+[(24/89)×(wt. ppm of Y)]+[(24/atomic weight of any other active element)×(wt. ppm of the said active element)] is greater than or equal to 20 and casting said substrate material as a single crystal having sulfur in an amount less than 0.3 ppm.15. A process according to claim 13 , wherein said casting step comprises using a master heat wherein the other active element is selected from the group consisting of elements in group IIA (Be claim 13 , Mg claim 13 , Ca claim 13 , . . . ) claim 13 , group IIIA (Sc claim 13 , Y claim 13 , La claim 13 , Ac) claim 13 , and group IVA (Ti claim 13 , Zr claim 13 , Hf) in the periodic table of elements claim 13 , with very high affinity to oxygen and sulfur are active elements. It is also understood that elements La and Ac also imply a series of rare earth elements such as Ce claim 13 , Gd claim 13 , and Er claim 13 , referred to as Lanthnides and Actinide series of elements claim 13 , with atomic numbers ranging from 57 to 71 and 89 to 103 claim 13 , respectively.16. A process according to claim 13 , wherein said overlay coating step comprises forming said overlay coating by EBPVD claim 13 , cathodic arc claim 13 , HVOF claim 13 , or other high ...

Подробнее
Номер записи: 75
12-04-2018 дата публикации

WEAR RESISTANT DISK BLADE AND AGRICULTURAL MACHINE WITH WEAR RESISTANT DISK BLADE

Номер: US20180098479A1
Автор: Augustine Brent A., Groves Tyler G., Martin Robert W., Nedved Peter R.
Принадлежит:

A disk blade having a circular blade body of a first base material of a first hardness and having top and a bottom surfaces and an outer edge extending around the blade body. At least one clad bead extends circumferentially about the blade body on the bottom surface adjacent the outer edge of a second hardness greater than the first hardness of the base material. Various bead patterns are possible. 1. A disk blade comprising:a circular blade body of a first base material having a first hardness and having top and a bottom surfaces and an outer edge extending around the periphery of the blade body;and at least one clad bead extending circumferentially about the blade body on the bottom surface adjacent the outer edge of a second hardness greater than the first hardness.2. The disk blade of wherein the at least one clad bead is straight circular bead extending about the disk body at a constant distance from the outer edge.3. The disk blade of further comprising a plurality of straight circular clad beads concentrically arranged relative to one another.4. The disk blade of wherein the clad beads are adjacent one another without any exposed base material between adjacent clad beads.5. The disk blade of wherein the clad beads are radially spaced from one another with exposed base material between adjacent clad beads.6. The disk blade of wherein the clad bead is in the form of a wave having smooth repetitive oscillations of varying distance from the outer edge.7. The disk blade of further comprising a plurality of wave beads concentrically arranged relative to one another.8. The disk blade of wherein the clad bead has a width of between 1.5 mm and 10 mm.9. The disk blade of wherein the clad bead has a width of between 10 mm and 40 mm.10. The disk blade of wherein the top surface of the blade body is formed with a beveled portion extending radially inward from outer edge a distance approximately equal to the width of the clad bead.11. The disk blade of having one circular ...

Подробнее
Номер записи: 76
04-04-2019 дата публикации

PEPTIDE FOR PROMOTING WOUND HEALING, ITS COMPOSITION AND METHOD OF USING THE SAME

Номер: US20190099466A1
Автор: Chen Syue-Ting, HUANG Min-Chuan, LIU YU-CHUN
Принадлежит: PRO SUNFUN BIOTECH RESEARCH AND DEVELOPMENT CO., LTD.

Disclosed is a peptide consisting of an amino acid sequence of HisThrSerThrGluAlaLys (SEQ ID NO: 1). This peptide is effective in the enhancement of fibroblast cell migration, which promotes wound healing. Also provided are a pharmaceutical composition for promoting wound healing comprising the peptide, and a method for promoting wound healing using the peptide. 12-. (canceled)3. A pharmaceutical composition for wound healing , comprisinga synthetic peptide consisting of the amino acid sequence of SEQ ID NO: 1 in an amount effective to enhance fibroblast cell migration and a pharmaceutically acceptable carrier.4. The pharmaceutical composition of claim 3 , wherein the composition is for systemic claim 3 , transdermal or topical administration.5. The pharmaceutical composition of claim 4 , wherein the composition is for topical administration.6. (canceled)7. The pharmaceutical composition of claim 5 , which is in a form of an ointment claim 5 , gel claim 5 , or emulsion.8. (canceled)9. The pharmaceutical composition of claim 5 , wherein the composition is for topical administration via a spray device claim 5 , a dressing or a paste.101. A method for promoting wound healing claim 5 , which comprises administering to a subject in need thereof the peptide of claim in an amount effective to enhance the fibroblast cell migration.11. A method for promoting wound healing claim 3 , which comprises administering to a subject in need thereof the composition of . The present invention relates generally to a peptide effective for promoting wound healing, its composition and method of using the same.Wound healing requires the coordination of several cell types including keratinocytes, fibroblasts, endothelial cells, macrophages and platelets. The process involves cell proliferation and migration, collagen deposition and remodeling, wound contraction and angiogenesis. Fibroblasts are the most important cells involved in producing and remodeling the extracellular matrix, and ...

Подробнее
Номер записи: 77
21-04-2016 дата публикации

MULTILAMINATE BACKING CONSTRUCTION

Номер: US20160106686A1
Автор: Audett Jay Douglas
Принадлежит: ALZA CORPORATION

A novel backing construction for a transdermal drug delivery system is disclosed. In particular, the invention relates to a system and method for labeling a transdermal drug delivery system, wherein the backing layer contains a writable medium capable of inkless printing. 117-. (canceled)18. A method of making a transdermal drug delivery device , the method comprising:forming a device comprising a primary drug-containing reservoir and multilaminate backing construction,wherein the primary drug-containing reservoir comprises a primary drug selected from the group consisting of a therapeutic agent and an antagonist, andwherein the multilaminate backing construction comprises(a) an outer layer,(b) a tie layer comprising a secondary drug-containing reservoir comprising a secondary drug selected from the group consisting of an antagonist and a therapeutic agent, wherein the secondary drug is different from the primary drug, and(c) a base layer.19. The method of claim 18 , wherein the tie layer is a multilaminate tie layer.20. The method of claim 19 , wherein the multilaminate tie layer comprises:a first layer disposed on the skin proximal surface of the outer layer;(ii) a second layer disposed on the skin proximal surface of the first layer;(iii) a third layer disposed on the skin proximal surface of the second layer; and(iv) the secondary drug-containing reservoir.21. The method of claim 20 , wherein the first layer is ethylene-vinyl acetate copolymer (EVA) or low density polyethylene (LDPE) layer; the second layer is a polyethylene terephthalate (PET) layer; and the third layer is an ethylene-vinyl acetate copolymer (EVA) claim 20 , a low density polyethylene (LDPE) claim 20 , or a polyurethane layer.22. The method of claim 18 , wherein the outer layer comprises a material selected from the group consisting of low density polyethylene (LDPE) claim 18 , medium density polyethylene (MDPE) claim 18 , high density polyethylene (HDPE) claim 18 , ultra high density ...

Подробнее
Номер записи: 78
21-04-2016 дата публикации

METHODS TO SENSE AND TREAT SUBCLINICAL SKIN DAMAGE

Номер: US20160106723A1
Автор: Ilowite Robert K.
Принадлежит:

A method of sensing and removing subclinical, precancerous cells from skin wherein the unblemished skin is not being treated for AK, fine lines or clinical wrinkles and is not chronically exposed to sun or UV radiations, the method comprising topically applying to skin of a patient a composition essentially comprising of an TLR7 agonist agent, Imiquimod in an amount effective to induce a cellular immune response in the skin resulting in the sensing and removal of subclinical, atypical keratinocytes by erythema, scaling, crusting, or combinations thereof. 1. A method of sensing and removing subclinical precancerous cells from unblemished skin without any clinical evidence of skin damage wherein the unblemished skin is not chronically exposed to sun or UV radiations , the method comprising:topically applying to skin of a patient a composition essentially comprising an immunomodulator in an amount effective to induce erythema, scaling, crusting, or combinations thereof.2. The method of claim 1 , wherein the subclinical precancerous cells are at a molecular stage and have not reached a detectable form.3. The method of claim 1 , wherein the immunomodulator agent is a TLR7 agonist.4. The method of claim 3 , wherein the TLR7 agonist agent consists essentially of Imiquimod.5. The method of claim 1 , wherein the composition is applied in a dosage in a range of 0.01 to 1 mg/cm.sup.2.6. The method of claim 1 , wherein the composition is administered in a cycle of therapy in the range of two to four weeks.7. The method of claim 1 , wherein the composition is administered once or twice daily during the cycle of therapy.8. The method of claim 1 , wherein the cycle of therapy is repeated at least once on a substantially annual basis.9. The method of claim 1 , wherein the composition further comprises one or more pharmaceutically acceptable carriers or excipients.10. A method of inducing a favorable immune cell response in skin having subclinical skin damage claim 1 , no previous ...

Подробнее
Номер записи: 79
21-04-2016 дата публикации

Method of Manufacturing Metal Containers

Номер: US20160107254A1
Автор: NEGRI LUCA
Принадлежит:

A method of manufacturing a container includes positioning metals plates against one another to define an interior space, filling the interior space with a granular refractory material and welding the seams between the plates to form a fluid tight container. 1. A method of manufacturing a container which comprisespositioning metal plates against one another to define an interior space; filling the interior space with a granular refractory material to prevent at least one of weld spatter from adhering to the interior of the container and to prevent burr from being created at the seams; andwelding the seams between the plates.2. A method as claimed in claim 1 , wherein granular refractory material comprises granules of crushed rock.3. A method as claimed in claim 2 , wherein the granules are rounded.4. A method as claimed in claim 2 , wherein the granules are angular.5. A method as claimed in claim 1 , wherein the granules having a diameter in the range from 3 mm to 4 mm.6. A method as claimed in any preceding claim 1 , wherein the refractory material is marble.7. A method as claimed in claim 1 , wherein the metal of which the plates are made is steel.8. A method as claimed in claim 1 , wherein the welding of the seams is performed by arc welding.9. A method as claimed in claim 1 , wherein the welding of the seams is performed using oxy-acetylene welding.10. A method as claimed in claim 1 , wherein the plates form a fluid tight container.11. A method as claimed in claim 1 , wherein the container is re-oriented during welding such that the granular refractory material contacts the seams. This application is the U.S. National Stage filing of International Application Serial No. PCT/EP2014/061716 filed on Jun. 5, 2014 which claims priority to Italian Application MO2013A000166 filed Jun. 7, 2013, each of which is incorporated herein by reference in its entirety.The present invention relates to a method of manufacturing metal containers.It is known to manufacture metal ...

Подробнее
Номер записи: 80
03-07-2014 дата публикации

COATED ARTICLE AND METHOD FOR MANUFACTURING THE SAME

Номер: US20140186649A1
Автор: WANG REN-BO
Принадлежит:

A coated article includes a metal substrate, a number of recesses defined in the metal substrate, and a plurality of sealing portions filled in the recesses. The sealing portions include metal, silicon oxide, aluminum oxide, sodium oxide, potassium oxide, and inorganic oxide pigment. The metal includes aluminum. A method for manufacturing the coated article is also provided. 1. A coated article comprising:a metal substrate;a plurality of recesses defined in a surface of the metal substrate; anda plurality of sealing portions filling the recesses; the sealing portions comprising:metal, silicon oxide, aluminum oxide, sodium oxide, potassium oxide, and inorganic oxide pigment; the metal comprising aluminum element.2. The coated article of claim 1 , the metal further comprising ferric element or titanium element .3. The coated article of claim 2 , wherein in the sealing portions claim 2 , the mass percentage of the metal is about 10% to about 18% claim 2 , the mass percentage of the silicon oxide is about 45% to about 63% claim 2 , the mass percentage of the aluminum oxide is about 6% to about 11% claim 2 , the mass percentage of the sodium oxide is about 5% to about 11% claim 2 , the mass percentage of the potassium oxide is about 4% to about 11% claim 2 , and the mass percentage of the inorganic oxide pigment is about 2.5% to about 6%.4. The coated article of claim 3 , wherein the inorganic oxide pigment comprises: ferric oxide claim 3 , calcium oxide claim 3 , cobalt oxide claim 3 , or titanium oxide.5. The coated article of claim 1 , wherein each sealing portion has a thickness of about 0.15 mm to about 0.35 mm.6. The coated article of claim 5 , wherein each sealing portion has a color different from the other sealing portions.7. The coated article of claim 1 , wherein each recesses has a depth of about 0.15 mm to about 0.35 mm.8. The coated ...

Подробнее
Номер записи: 81
23-04-2015 дата публикации

TOPICAL REGIONAL NEURO-AFFECTIVE THERAPY

Номер: US20150111930A1
Автор: Aung-Din Ronald
Принадлежит: Afgin Pharma, LLC

A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy is disclosed. 1. A method of treating a disease state or condition in humans with a drug comprising administering a drug comprising 4-aminopyridine or a pharmaceutically acceptable derivative thereof useful for topical regional neuro-affective therapy , in a therapeutically effective amount to treat the disease state or condition , to the back of the neck at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy to the patient.2. The method of claim 1 , wherein the drug is 4-aminopyridine.3. (canceled)4. The method of claim 2 , wherein the drug is 3 claim 2 ,4 diaminopyridine.5. The method of claim 1 , wherein the disease state or condition is selected from the group consisting of benign essential/familial tremor claim 1 , tremor related to multiple sclerosis (MS) claim 1 , chronic encepahalopathies such as from stroke or head injuries claim 1 , congenital CNS degeneration conditions/cerebral palsy claim 1 , cerebellar degeneration syndromes claim 1 , and a spastic conditions.6. (canceled)7. The method of claim 2 , wherein the condition is multiple sclerosis (MS).824-. (canceled)25. The method of claim 1 , wherein the drug is formulated in a pharmaceutically acceptable immediate release topical carrier.26. The method of claim 25 , wherein the carrier is aqueous-based.27. The method of claim 1 , further comprising formulating the 4-aminopyridine or a pharmaceutically acceptable derivative thereof in a pharmaceutically acceptable immediate release aqueous-based carrier claim 1 , and applying a sufficient amount to the back of the neck at the hairline (“BONATH”) of the human ...

Подробнее
Номер записи: 82
23-04-2015 дата публикации

METHODS OF MODULATING STEROID HORMONE ACTIVITY

Номер: US20150111973A1
Автор: BAUMAN SUSANNE, Kelce William Reed
Принадлежит: Novan, iNC.

The present invention relates to methods of treating steroid hormone related disorders by modulating steroid hormone activity. 1. A method of treating a steroid hormone related disorder in the skin of a subject , the method comprising:administering a nitric oxide-releasing pharmaceutical composition to the skin of the subject to locally modulate steroid hormone activity in the skin of the subject, thereby treating said steroid hormone related disorder in the skin of the subject.2. The method of claim 1 , wherein the nitric oxide-releasing pharmaceutical composition comprises at least one nitric oxide releasing active pharmaceutical ingredient.3. (canceled)4. The method of claim 2 , wherein the at least one nitric oxide releasing active pharmaceutical ingredient comprises a diazeniumdiolate functional group.5. The method of claim 2 , wherein the at least one nitric oxide releasing active pharmaceutical ingredient comprises NO-releasing co-condensed silica particles.67.-. (canceled)8. The method of claim 1 , wherein the steroid hormone activity is locally modulated at a follicular steroid hormone target in the skin of the subject.9. The method of claim 1 , wherein locally modulating comprises decreasing steroid hormone activity.1018.-. (canceled)19. The method of claim 1 , wherein the nitric oxide-releasing pharmaceutical composition is administered to the skin of the subject with no systemic nitric oxide effects.20. A method of reducing steroid hormone induced sebum production in the skin of a subject claim 1 , the method comprising:administering a nitric oxide-releasing pharmaceutical composition to the skin of the subject to locally modulate steroid hormone activity in the skin of the subject, thereby reducing sebum production in the skin of the subject.21. The method of claim 20 , wherein the nitric oxide-releasing pharmaceutical composition comprises at least one nitric oxide releasing active pharmaceutical ingredient comprising a diazeniumdiolate functional ...

Подробнее
Номер записи: 83
20-04-2017 дата публикации

COMPOSITIONS AND METHODS OF TREATMENT OF INFLAMMATORY SKIN CONDITIONS USING ALLANTOIN

Номер: US20170105967A1
Автор: FARBER Elliott, Ryan Robert
Принадлежит: Scioderm, Inc.

Embodiments herein provide formulations and methods for treatment of inflammatory skin diseases using allantoin in an amount from about 0.5% to about 15.0% by weight. Inflammatory skin diseases treated by embodiments herein include, without limitation, cutaneous porphyria, sclerodema, epidermolysis bulosa, psoriasis, decubitus ulcers, pressure ulcers, diabetic ulcers, venous stasis ulcers, sickle cell ulcers, ulcers caused by burns, eczema, urticaria, atopic dermatitis, dermatitis herpetiform, contact dermatitis, arthritis, gout, lupus erythematosus, acne, alopecia, carcinomas, psoriasis, rosacea, miliaria, skin infections, post-operative care of incisions, post-operative skin care following any variety of plastic surgery operations, skin care following radiation treatment, care of dry, cracked or aged skin and skin lines as well as other conditions affecting the skin and having an inflammatory component, symptoms thereof, or a combination thereof. Symptoms treated may include pain, inflammation, redness, itching, scarring, skin thickening, milia, or a combination thereof. 1. A composition comprising an oil-in-water emulsion comprising allantoin in an amount from about 2.5% to about 15% by weight and a pharmaceutically acceptable excipient.23-. (canceled)4. The composition of further comprising an emollient claim 1 , an emulsifier claim 1 , a solvent claim 1 , a pH modifier claim 1 , a solubilizing agent claim 1 , an antioxidant claim 1 , a preservative claim 1 , a chelating agent claim 1 , an additive claim 1 , a viscosity agent or a combination thereof.513-. (canceled)14. A method of treating inflammatory skin conditions in a patient comprising administering the composition of claim 1 , wherein said inflammatory skin condition in said patient is treated.15. The method of claim 14 , wherein the composition further comprises an emollient claim 14 , an emulsifier claim 14 , a solvent claim 14 , a pH modifier claim 14 , a solubilizing agent claim 14 , an antioxidant ...

Подробнее
Номер записи: 84
02-04-2020 дата публикации

TOPICAL ANTIMICROBIAL COMPOSITIONS AND METHODS OF FORMULATING THE SAME

Номер: US20200101082A1
Автор: II Jay Richard, Ray
Принадлежит: CMPD LICENSING, LLC

A method of treating a bacterial infection of a subject includes topically administering a topical composition that includes cefixime combined with a carrier. The topical composition may be administered by contacting a tissue surface of the subject to be treated with the topical composition such as skin or mucosal tissue. 1. A method of treating a bacterial infection of a subject , the method comprising:topically administering a topical composition to the subject comprising contacting a tissue surface of the subject to be treated with the topical composition,wherein the tissue surface comprises skin or mucosal tissue, andwherein the topical composition comprises cefixime combined with a carrier.2. The method of claim 1 , wherein the topical composition is administered in a dosage amount of between approximately 200 mg and approximately 400 mg cefixime.3. The method of claim 1 , wherein the topical composition is topically administered once or twice daily.4. The method of claim 3 , wherein the topical composition is topically administered twice daily and the topical composition comprises approximately 400 mg cefixime in each topical administration.5. The method of claim 1 , wherein the carrier comprises an aqueous solution and the topical composition comprises a solution format.6. The method of claim 5 , wherein the tissue surface comprises an ear of the subject claim 5 , and wherein administering the topical composition comprises administering the solution to an ear canal in one or more drops.7. The method of claim 5 , wherein the tissue surface comprises a lung of the subject claim 5 , and wherein administering the topical composition comprises nebulizing the solution for inhalation by the subject to deliver the topical composition to an infected mucosal tissue of the lung.8. The method of claim 5 , wherein the tissue surface comprises a nasal cavity of the subject claim 5 , and wherein administering the topical composition comprises contacting infected mucosal ...

Подробнее
Номер записи: 85
02-04-2020 дата публикации

Photosensitive Dyes and Method of Using Said Dyes

Номер: US20200101161A1
Автор: Titlebaum Richard, Tyagi Som
Принадлежит: STRT LLC

A bandage and a method of treating a wound with the bandage is provided. The method includes the steps of applying a photosensitive dye to the wound; covering the wound with a bandage; and applying a light to the dye such that the dye generates a reactive oxygen species. 1. A method of treating a wound comprising the steps of:(a) applying a photosensitive dye to the wound;(b) covering the wound with a bandage;and(c) applying a light to the dye such that the dye generates a reactive oxygen species.2. The method according to claim 1 , further comprising claim 1 , between steps (b) and (c) claim 1 , the step of wetting the wound.3. The method according to claim 1 , wherein step (b) comprises using an opaque bandage and wherein the method further comprises claim 1 , between steps (b) and (c) claim 1 , the step of moving at least part of the bandage away from the wound.4. The method according to claim 3 , further comprising claim 3 , after step (c) claim 3 , re-covering the wound with the bandage.5. The method according to claim 1 , wherein steps (a) and (b) are performed in a clinical environment and wherein step (c) is performed outside of the clinical environment.6. A method of bandaging a wound comprising the steps of:(a) applying a photosensitive dye to the wound;(b) covering the wound with a bandage;(c) wetting the dye; and(d) applying a light to the dye such that the dye generates a reactive oxygen species.7. The method according to claim 6 , wherein the dye comprises a liquid.8. The method according to claim 6 , wherein the dye comprises a solid.9. The method according to claim 6 , wherein the dye is incorporated into the bandage and wherein steps (a) and (b) are performed simultaneously.10. The method according to claim 6 , wherein step (c) comprises wetting the dye from natural fluid from the wound.11. The method according to claim 6 , wherein step (c) comprises wetting the dye from an external fluid source.12. The method according to claim 6 , wherein step (d) ...

Подробнее
Номер записи: 86
30-04-2015 дата публикации

PREPARATION FOR PERCUTANEOUS ABSORPTION CONTAINING ROTIGOTINE

Номер: US20150118309A1
Автор: Hwang Yong-Youn, Im Jong-Seob, Kim Hun-Taek, Kim Hye-Min, Oh Joon-Gyo, Park Yeo-Jin, Youn Won-No
Принадлежит:

Exemplary embodiments of the present invention relate to a method for preparing a preparation for percutaneous absorption, which includes rotigotine as an active ingredient, and more specifically, to a method for preparing a preparation for percutaneous absorption including mixing rotigotine and an ethylene-vinyl acetate adhesive so as to have a weight ratio of 1:(0.1 to 20), a preparation for percutaneous absorption manufactured by the method, and a percutaneous treatment system. The preparation and the system may prevent separation of the rotigotine, thereby increasing long-term storage stability, and effectively release the rotigotine, and thus can be effectively applied to preparing patch medication containing the rotigotine. 1. A method for preparing a transdermally absorbable preparation , the method comprising:mixing rotigotine and an ethylene-vinyl acetate (EVA) adhesive at a weight ratio of 1:(0.1 to 20).2. The method of claim 1 , wherein the rotigotine and the ethylene-vinyl acetate adhesive are mixed at a weight ratio of 1:(0.3 to 20).3. A transdermally absorbable preparation prepared by the method of .4. A transdermally absorbable preparation prepared by the method of .4. A transdermal therapeutic system claim 2 , comprising:a drug-containing matrix layer comprising rotigotine and an ethylene-vinyl acetate adhesive at a weight ratio of 1:(0.1 to 20); anda substrate to support the drug-containing matrix layer.5. The transdermal therapeutic system of claim 4 , wherein the drug-containing matrix layer comprises the rotigotine and the ethylene-vinyl acetate adhesive at a weight ratio of 1:(0.3 to 20). This application is a continuation of International Application No. PCT/KR2013/006060, filed on Jul. 8, 2013, and claims priority from and the benefit of Korean Patent Application No. 10-2012-0073798 filed on Jul. 6, 2012, each of which is hereby incorporated by reference for all purposes as if fully set forth herein.1. FieldExemplary embodiments of the present ...

Подробнее
Номер записи: 87
10-07-2014 дата публикации

TOPICAL ANTIBIOTIC COMPOSITION FOR THE PREVENTION OF LYME DISEASE

Номер: US20140194375A1
Автор: HUBER Gustave, ROOSENS-VON BIDDER Caroline, UTA Huttenes
Принадлежит: Ixodes AG

The invention relates to topical pharmaceutical compositions and methods related to toxins, in particular, the present invention provides compositions and methods for the treatment of infections caused by and in particular for the prevention of Lyme disease. 112-. (canceled)13. A process for the preparation of a topical pharmaceutical composition for the prevention of Lyme disease comprising combining azithromycin , a solvent with greater volatility than water , a solvent less volatile than water , and a solidifying agent.14Borrelia burgdorferi. A process for the preparation of a topical pharmaceutical composition for the elimination of resulting from a tick bite comprising combining azithromycin , a solvent with greater volatility than water , a solvent less volatile than water , and a solidifying agent.15Borrelia burgdorferi. A topical pharmaceutical composition for the prevention of Lyme disease or for the elimination of spirochetal , cystic and/or spherical forms of resulting from a tick bite , comprising azithromycin , a solvent with greater volatility than water , a solvent less volatile than water , and a solidifying agent.16. The topical pharmaceutical composition according to claim 15 , wherein the azithromycin is present from about 1 wt % to about 30 wt % claim 15 , based on the total weight of the composition.17. The topical pharmaceutical composition according to claim 15 , wherein the solvent with greater volatility than water is present from about 40 wt % to about 99 wt % claim 15 , based on the total weight of the composition.18. The topical pharmaceutical composition according to claim 15 , wherein the solidifying agent is present from about 5 wt % to about 60 wt % claim 15 , based on the total weight of the composition.19. The topical pharmaceutical composition according to claim 15 , wherein the solvent less volatile than water is present from about 2 wt % to about 30 wt % claim 15 , based on the total weight of the composition.20. The topical ...

Подробнее
Номер записи: 88
09-06-2022 дата публикации

TREATMENT OF SKIN LESIONS AND PRURITUS IN PRURIGO NODULARIS PATIENTS

Номер: US20220177568A1
Автор: PIKETTY Christophe
Принадлежит: Galderma Holding SA

Disclosed herein are methods for selectively treating pruritus in a subject having chronic prurigo (CP), including prurigo nodularis (PN), pharmaceutical compositions for use in the treatment of pruritus in a subject having CP or PN, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of pruritus in a subject having CP or PN. 129.-. (canceled)30. A method of treating skin lesions and pruritus in a subject having chronic prurigo (CP) , comprising administering about 30 mg to about 60 mg of nemolizumab or an equivalent thereof to the subject.31. The method of claim 30 , wherein the subject has prurigo nodularis (PN).32. The method of claim 31 , wherein the subject has been diagnosed of PN for at least about 6 months.33. The method of claim 30 , wherein the subject has at least about 20 nodules on his/her body with a bilateral distribution.34. The method of claim 30 , wherein the subject has prurigo lesions on upper limbs.35. The method of claim 30 , wherein the pruritus has been assigned a score of at least 4 on the Numerical Rating Scale (NRS).36. The method of claim 30 , wherein the pruritus has been assigned a score of at least 7 on the Numerical Rating Scale (NRS).37. The method of claim 30 , wherein the subject does not have atopic dermatitis.38. The method of claim 30 , wherein the nemolizumab or the equivalent thereof is administered to the subject according to a flat dosing regimen.39. The method of claim 30 , wherein the nemolizumab or the equivalent thereof is administered to the subject according to a loading dose regimen.40. The method of claim 30 , wherein 30 mg or 60 mg of nemolizumab or the equivalent thereof is administered to the subject.41. The method of claim 30 , wherein the nemolizumab or the equivalent thereof is administered to the subject once every four weeks.42. The method of claim 30 , wherein the nemolizumab or the equivalent thereof is administered subcutaneously.43. A method of treating ...

Подробнее
Номер записи: 89
18-04-2019 дата публикации

BUILD-UP WELDING METHOD

Номер: US20190111510A1
Автор: Plasch Siegfried
Принадлежит:

A build-up welding method () is disclosed in which a welding torch () is guided along a metallic workpiece () and at least one melting wire () serving as a build-up material () is fed at an infeed speed () into the arc () between at least one non-melting electrode () of the welding torch () and the workpiece (). In order to achieve a build-up welding method () with higher build-up speeds in comparison to the prior art, it is proposed for the non-melting electrode () positioned normal to the workpiece () to be guided along the workpiece () and for the fed wire () to also be moved back and forth along its infeed direction (). 1. A build-up welding method , comprising:guiding a welding torch along a metallic workpiece;feeding at least one melting wire serving as a build-up material at an infeed speed into an arc between at least one non-melting electrode of the welding torch and the workpiece; andguiding the non-melting electrode, positioned normal to the workpiece, along the workpiece and moving the melting wire back and forth along an infeed direction of the melting wire.2. The build-up welding method according to claim 1 , comprising feeding the melting wire into the arc in advance in guidance direction of the welding torch.3. The build-up welding method according to claim 1 , comprising feeding the melting wire continuously.4. The build-up welding method according to claim 1 , wherein the non-melting electrode has a diameter of at least 6.4 mm.5. The build-up welding method according to claim 1 , comprising guiding the welding torch along an outer cylindrical surface of a pipe.6. The build-up welding method according to claim 5 , comprising guiding the welding torch along an inner cylindrical surface of the pipe.7. The build-up welding method according to claim 1 , comprising guiding the welding torch along the workpiece in a circular or serpentine fashion.8. The build-up welding method according to claim 1 , wherein the non-melting electrode is a tungsten ...

Подробнее
Номер записи: 90
07-05-2015 дата публикации

LASER CLADDING WITH A LASER SCANNING HEAD

Номер: US20150122783A1
Автор: Cavanaugh Daniel, Embrey Justin Curtis, LUICK KEGAN, Marchione Thierry Andre, Walker Waylon Scott
Принадлежит: CATERPILLAR INC.

A method for laser cladding a material onto a surface of a machine component using a laser scanning head with laser scanning optics is disclosed. The method includes forming a molten bead of cladding material by directing a beam with the laser scanning optics over a bead scan on the machine component. The method also includes directing the beam with the laser scanning optics over a secondary scan on the machine component, the secondary scan being offset from the bead scan at a predetermined distance on the machine component. 1. A method for laser cladding a material onto a surface of a machine component using a laser scanning head with laser scanning optics , the method comprising:forming a molten bead of cladding material by directing a beam with the laser scanning optics over a bead scan on the machine component; anddirecting the beam with the laser scanning optics over a secondary scan on the machine component, the secondary scan being offset from the bead scan at a predetermined distance on the machine component.2. The method of claim 1 , wherein the secondary scan is a pre-clean scan performed forward of the bead scan to clean and prepare the surface to receive a subsequent bead.3. The method of claim 1 , wherein the secondary scan is a pre-heat scan performed forward of the bead scan to pre-heat and prepare the surface to receive a subsequent bead.4. The method of claim 1 , wherein the secondary scan is a post-heat scan performed aft of the bead scan to re-heat a previously formed bead.5. The method of claim 1 , wherein a first number of passes for the bead scan is performed prior to the secondary scan and a second number of passes for the bead scan is performed after the secondary scan.6. The method of claim 2 , further comprising pre-heating the surface by directing the beam over a pre-heat scan forward of the bead scan to prepare the surface to receive a subsequent bead.7. The method of claim 6 , further comprising post-heating a previously formed bead by ...

Подробнее
Номер записи: 91
05-05-2016 дата публикации

TOPICAL TREATMENT OF LOCALIZED SCLERODERMA

Номер: US20160120865A1
Автор: Lafyatis Robert Alan, Majhi Pinaki Ranjan, Redmon Martin P., Trumbore Mark W.
Принадлежит:

Disclosed are compositions and formulations for topical administration that contain a tyrosin kinase inhibitor, such as imatinib or nilotinib. The topical compositions or formulations are useful in treating scleroderma. 1. A method of treating scleroderma , comprising the step of applying topically to an affected area of skin of a subject in need thereof a composition or a formulation comprising a therapeutically-effective amount of a tyrosine kinase inhibitor; and a dermatologically acceptable carrier or excipient.2. The method of claim 1 , wherein the tyrosine kinase inhibitor is effective against BCR-ABL tyrosine kinase claim 1 , c-Abl tyrosine kinase claim 1 , α-PDGFR claim 1 , β-PDGFR claim 1 , or KIT receptor kinase claim 1 , or inhibits TGF-β.3. The method of claim 1 , wherein the tyrosine kinase inhibitor is imatinib or nilotinib.4. The method of claim 1 , wherein the tyrosine kinase inhibitor is imatinib.5. The method of claim 1 , wherein the tyrosine kinase inhibitor is AG 18 claim 1 , DMPQ claim 1 , PD 166285 claim 1 , PPY A claim 1 , SU 16f claim 1 , SU 5416 claim 1 , SU 6668 claim 1 , or sunitinib.6. The method of any one of - claim 1 , wherein the tyrosine kinase inhibitor is dissolved in the carrier or excipient.7. The method of any one of - claim 1 , wherein the composition or formulation is a cream claim 1 , a lotion claim 1 , a solution claim 1 , a gel claim 1 , or an ointment.8. The method of any one of - claim 1 , wherein the carrier or excipient is a gel.9. The method of claim 8 , wherein the carrier or excipient is an anhydrous gel.10. The method of any one of - claim 8 , wherein the composition or formulation is a spray.11. The method of any one of - claim 8 , wherein the composition or formulation is non-irritating.12. The method of any one of - claim 8 , wherein the composition or formulation is well-tolerated.13. The method of any one of - claim 8 , wherein the composition or formulation reduces inflammation.14. The method of any one of - ...

Подробнее
Номер записи: 92
04-05-2017 дата публикации

3-METHANESULFONYLPROPIONITRILE FOR TREATING INFLAMMATION AND PAIN

Номер: US20170119725A1
Автор: St. Laurent Joseph
Принадлежит:

The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. 1. A method of reducing or alleviating symptoms of localized manifestations of inflammation characterized by acute or chronic swelling , pain , or redness , comprising the steps of:identifying a subject suffering from localized manifestations of inflammation, andadministering to the subject a compound of 3-methanesulfonylpropionitrile, or a pharmaceutically acceptable salt thereof, in an amount effective to treat the localized manifestations of inflammation.2. The method according to claim 1 , wherein said symptoms are characterized by localized acute or chronic swelling.3. The method according to claim 1 , wherein said compound is orally administered.4. The method according to claim 1 , wherein said compound is topically administered.5. A method of treating inflammation and/or pain associated with inflammatory joints claim 1 , ligaments claim 1 , tendons claim 1 , bone claim 1 , muscles claim 1 , or fascia claim 1 , comprising the steps of:identifying a subject in need thereof, andadministering to the subject 3-methanesulfonylpropionitrile, or a pharmaceutically acceptable salt thereof, in an amount effective to treat the inflammation and/or pain associated with joints, ligaments, tendons, bone, muscles, or fascia.6. The method according to claim 5 , wherein said method treats inflammation and/or pain associated with rheumatoid arthritis.7. The method according to ...

Подробнее
Номер записи: 93
24-07-2014 дата публикации

Bodily Cooling Fluid Techniques

Номер: US20140205554A1
Автор: Beckman Christopher V.
Принадлежит:

New bodily cooling techniques are provided. In some aspects of the present invention, a new rapidly-evaporating cooling gel or fluid is sprayed or doused over or about an athlete's body and/or worn garments in thermal-reduction-optimized gravitational, diffusion and movement-induced patterns, to maximize cooling during exercise. In some aspects, a worn garment may serve as the matrix or platform for this distribution of the fluid. In other aspects, tuned, heat-absorbing port-controlling devices cause the release of the cooling gel or fluid from distribution tubes or other channels (e.g., integral to the flexible fabric itself) upon local underlying body heat exceeding a threshold, and resealing (halting release) upon body or regional heat dropping below a threshold. 1. An externally applicable cooling enhancement composition , comprising deionized water , purified water , filtered water or other lowered-ionization water and another a transpiration cooling component or agent with a volatility greater than water.2. The externally applicable cooling enhancement composition of claim 1 , in which said transpiration cooling component or agent comprises an alcohol or combination of alcohols.3. The externally applicable cooling enhancement composition of claim 2 , in which said alcohol or combination comprises isopropyl alcohol.4. The externally applicable cooling enhancement composition of claim 2 , in which said alcohol or combination comprises ethyl alcohol.5. The externally applicable cooling enhancement composition of claim 2 , in which said alcohol or combination of alcohols is of a low enough proportion to avoid any significant irritation or other adverse health effects for at least a majority of users due to said alcohol or combination of alcohols.6. The externally applicable cooling enhancement composition of claim 1 , further comprising a preservative and/or stabilizing agent.7. The externally applicable cooling enhancement composition of claim 1 , further ...

Подробнее
Номер записи: 94
31-07-2014 дата публикации

CLADDING OF ALLOYS USING FLUX AND METAL POWDER CORED FEED MATERIAL

Номер: US20140209577A1
Автор: Bruck Gerald J., Kamel Ahmed
Принадлежит:

A metal cladding process utilizing a feed material () formed as a hollow sheath () containing a powdered core () including powdered metal and powdered flux material. The powdered metal and flux may have overlapping mesh size ranges. The sheath may be an extrudable subset of elements of a desired superalloy cladding material, with the powdered metal and powdered flux materials complementing the sheath to form the desired superalloy material when melted. The powdered metal may include an excess of titanium to compensate for a reaction of titanium with oxygen or carbon dioxide in a shielding gas. Heat for melting may be provided by an energy beam () or by utilizing the feed material as an electrode in a cold metal arc welding torch (). 1. A method comprising:providing a feed material comprising a sheath containing a powdered core material, the powdered core material comprising powdered metal material and powdered flux material;melting the feed material onto a substrate to form a melt pool; andallowing the melt pool to cool to form a layer of clad material of a desired composition covered by a layer of slag.2. The method of claim 1 , further comprising:selecting the sheath to be formed of an extrudable subset of elements of a desired superalloy material; andselecting the powdered metal and powdered flux materials to comprise elements that complement the sheath to form the clad material as the desired superalloy material when melted onto the substrate.3. The method of claim 2 , further comprising forming the sheath from one of the group of nickel claim 2 , nickel-chromium claim 2 , and nickel-chromium-cobalt.4. The method of claim 1 , further comprising:selecting the desired composition of clad material to include titanium;providing a shielding gas comprising carbon dioxide or oxygen during the step of melting; andproviding the powdered core material to comprise titanium to compensate for a loss of titanium due to reaction with the oxygen or carbon dioxide and subsequent ...

Подробнее
Номер записи: 95
10-05-2018 дата публикации

NEW TARGETS FOR RNA THERAPEUTICS

Номер: US20180126003A1
Автор: Hoerr Ingmar
Принадлежит:

The present invention relates to a method for treating or preventing a disease, disorder or condition by administration of a polynucleotide, e.g. a modified RNA, encoding a peptide or protein related to this disease, disorder or condition. The present invention also relates to pharmaceutical compositions for use in such method. 1. A method for treating or preventing a disease , disorder or condition in a subject in need thereof by increasing the level of at least one peptide or protein related to this disease , disorder or condition comprising administering to the subject a pharmaceutical composition comprising at least one polynucleotide encoding said at least one peptide or protein ,wherein said at least one peptide or protein is selected from the group consisting of peptides and proteins listed in column 1 (c1) of Table 1 and wherein the disease, disorder or condition to which said at least one peptide or protein relates is selected from the group consisting of diseases, disorders and conditions listed in column 7 (c7) of Table 1,wherein the at least one peptide or protein and the disease, disorder or condition to which said at least one peptide or protein relates are listed in the same entry of Table 1 in column 7 (c1).2. A method for reducing and/or ameliorating at least one symptom of a disease , disorder or condition in a subject in need thereof by increasing the level of at least one peptide or protein related to this disease , disorder or condition comprising administering to the subject a pharmaceutical composition comprising a polynucleotide encoding said at least one peptide or protein ,wherein said at least one peptide or protein is selected from the group consisting of peptides and proteins listed in column 1 (c1) of Table 1 and wherein the disease, disorder or condition to which said peptide or protein relates is selected from the group consisting of diseases, disorders and conditions listed in column 7 (c7) of Table 1,wherein the at least one peptide ...

Подробнее
Номер записи: 96
11-05-2017 дата публикации

TSLP INDUCES NEUTROPHIL MEDIATED KILLING OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS

Номер: US20170128535A1
Автор: Garcia K. Christopher, Leonard Warren Jaye, Spolski Rosanne, West Erin Elizabeth
Принадлежит:

The invention provides a method of promoting the host defense of a patient to a bacterial infection comprising administering to a patient suffering or at risk of a bacterial infection, a pharmaceutical composition comprising an effective amount of the pleiotropic cytokine, thymic stromal lymphopoietin (TSLP) protein or polypeptide in an amount and at a location sufficient to promote the host defense of the patient to the bacterial infection. In a preferred embodiment, the bacterial infection is the infection of the patient with MRSA. 1Staphylococcus aureusStreptococcus pyogenes.. A method of promoting the host defense of a human patient to a bacterial infection comprising administering to a human patient suffering from or at risk of a bacterial infection , a pharmaceutical composition comprising an effective amount of a thymic stromal lymphopoeitin (TSLP) protein or polypeptide in an amount sufficient to promote the host defense of the patient to the bacterial infection , wherein the bacterial infection is the infection of the patient with or2. The method of claim 1 , wherein the patient is suffering from the bacterial infection.3. The method of claim 1 , wherein the patient is at risk of contracting the bacterial infection.4Staphylococcus aureus. The method of claim 1 , wherein the bacterial infection is the infection of the patient with Methicillin-resistant (MRSA).5. The method of claim 1 , wherein the TSLP protein or polypeptide comprises or consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-3 or 7-11 claim 1 , a sequence 90% identical an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3 or 7-11 claim 1 , a functional variant of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3 or 7-11 claim 1 , or a combination thereof.6. The method of claim 1 , wherein the pharmaceutical composition is formulated for topical application to a barrier tissue of the patient.7. The ...

Подробнее
Номер записи: 97
02-05-2019 дата публикации

METHOD FOR SETTING UP A ROTARY PROCESSING MACHINE AND ROTARY PROCESSING MACHINE

Номер: US20190126403A1
Автор: Rettich Thorsten
Принадлежит: J.G. WEISSER SOHNE GMBH & CO. KG

A method for setting up a rotary processing machine (), in which at least one base jaw () of a workpiece receptacle is set up to receive a workpiece type that is to be processed and in which the base jaw () is coated on a workpiece contact surface (). 11. A method for setting up a rotary processing machine () , the method comprising:{'b': 4', '2', '4', '11, 'setting up a base jaw () of a workpiece receptacle () to receive a workpiece type that is to be processed by coating the base jaw () on a workpiece contact surface ().'}24. The method as claimed in claim 1 , the coating is executed on the base jaw () in an installed position on the rotary processing machine.3413115. The method as claimed in claim 1 , further comprising after the coating claim 1 , machining the base jaw () using a tool () arranged in a working position of the rotary processing machine () on the coated workpiece contact surface ().41015. The method as claimed in claim 1 , wherein the coating is accomplished by friction of a consumable material () on the workpiece contact surface ().5. The method as claimed in claim 4 , wherein at least one of steel claim 4 , non-ferrous metal claim 4 , or plastic is used as the consumable material.6. The method as claimed in claim 1 , wherein the coating is accomplished by at least one of laser sintering or by electric arcs.7. The method as claimed in claim 1 , further comprising applying an adhesive-friction enhancing coating via the coating.81. A rotary processing machine () comprising:{'b': 2', '4', '6', '4', '15, 'a workpiece receptacle (), which has at least one base jaw (); and a coating device () by which the base jaw () is adapted to be coated on a workpiece contact surface ().'}911312154. The rotary processing machine () as claimed in claim 8 , further comprising a tool () clamped in a tool receptacle () claim 8 , by which the workpiece contact surface () of the base jaw () is machined.10681010. The rotary processing machine as claimed in claim 8 , ...

Подробнее
Номер записи: 98
19-05-2016 дата публикации

METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION

Номер: US20160136137A1
Автор: Duffy Erin M.
Принадлежит:

The present invention relates to methods for treating acne and other skin infections caused or mediated by , or in a patient with a safe and effective amount of a topically applied oxazolidinone antibiotic compound. 117-. (canceled)19. The method according to claim 18 , wherein the compound is a pharmaceutically acceptable salt selected from the group consisting of acetate claim 18 , ascorbate claim 18 , benzoate claim 18 , citrate claim 18 , esylate claim 18 , ethanedisulfonate claim 18 , fumarate claim 18 , hydrochloride claim 18 , lactate claim 18 , maleate claim 18 , mesylate claim 18 , phosphate claim 18 , pyroglutamate claim 18 , salicylate claim 18 , succinate claim 18 , sulfate claim 18 , tartrate claim 18 , and tosylate.20. The method according to claim 18 , wherein the skin infection is treated in the patient.21. The method according to claim 18 , wherein the skin infection is prevented in the patient.22. The method according to claim 18 , wherein the method reduces the risk of the skin infection in the patient.23Propionibacterium acnes.. The method according to claim 18 , wherein the skin infection is caused or mediated by24Staphylococcus aureus.. The method according to claim 18 , wherein the skin infection is caused or mediated by25Gardnerella vaginalis.. The method according to claim 18 , wherein the skin infection is caused or mediated by26. The method according to claim 18 , wherein the skin infection is selected from acne vulgaris claim 18 , rosacea claim 18 , impetigo claim 18 , otitis externa claim 18 , bacterial conjunctivitis claim 18 , and bacterial vaginosis.27. The method according to claim 18 , wherein the skin infection is acne vulgaris.28. The method according to claim 18 , wherein the skin infection is bacterial vaginosis.29. The method according to claim 18 , wherein the compound is administered orally claim 18 , parenterally claim 18 , or topically.30. The method according to claim 18 , wherein the compound is administered topically. ...

Подробнее
Номер записи: 99
19-05-2016 дата публикации

CLADDING METHOD FOR VALVE SEAT AND PRODUCTION METHOD FOR CYLINDER HEAD

Номер: US20160136758A1
Автор: Kawasaki Minoru, KIDERA Kenji, SHODA Yoshiji
Принадлежит: TOYOTA JIDOSHA KABUSHIKI KAISA

A cladding method for a valve seat in a cylinder head blank includes a combustion chamber, an intake port or an exhaust port communicating with the combustion chamber, and an annular countersunk groove formed in an opening end of the port on the combustion chamber side, the method being for forming a cladding layer by irradiating metal powder supplied in the countersunk groove with a laser beam. A gas flow regulating wall is provided, which projects from the countersunk groove to an inner side of the countersunk groove and to the combustion chamber side, gas is sprayed during irradiating with the laser beam, and the gas is flown by the gas flow regulating wall from the inner side to an outer side of the countersunk groove. 113-. (canceled)15. The cladding method for a valve seat according to claim 14 , wherein the gas is discharged from a laser machining head that emits the laser beam.16. The cladding method for a valve seat according to claim 15 , wherein the metal powder is discharged together with the gas from the laser machine head.17. The cladding method for a valve seat according to claim 15 , wherein an optical axis of the laser beam is coaxial with a discharge axis of the metal powder.18. The cladding method for a valve seat according to claim 14 , wherein the gas flow regulating wall is formed so as to be detachable from the cylinder head blank.19. The cladding method for a valve seat according to claim 14 , wherein the gas flow regulating wall is formed integrally with the cylinder head blank.20. A production method for a cylinder head claim 14 , comprising:a first step of forming a cylinder head blank provided with an intake port and an exhaust port communicating with a combustion chamber;a second step of forming an annular countersunk groove in an opening end of at least one of the intake port and the exhaust port on a combustion chamber side;a third step of providing a gas flow regulating wall projecting from the countersunk groove to an inner side of ...

Подробнее
Номер записи: 100